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ABSTRACT 
Human Coronavirus NL-63 is a respiratory virus with a high incidence rate, 
causing mild respiratory infections in children under the age of 18. The outbreak 
of Sever Acute Respiratory Syndrome (SARS) in 2003 sparked increased interest 
into the field of coronavirology and respiratory diseases subsequently led to the 
discovery of this novel Human Coronavirus (HCoV) by a group of scientists in 
Holland. 
 
The membrane protein (M) of NL-63 has been shown to interact with the 
nucleocapsid, spike and envelope proteins of the virus when expressed ex vivo. 
In contrast, the envelope protein (E) is shown to exhibit ion channel activity, 
interacts with the membrane protein during the formation of viral-like particles.. 
The functions of the open reading frame 3 (ORF3) proteins remains a mystery. 
Research does, however, indicate that this protein is needed for in vivo infectivity 
and pathogenesis. 
 
Bioinformatic analysis indicates that both the ORF3 and M proteins posses at 
least 3’ C-terminal transmembrane regions. To further characterize the biological 
activity of these three proteins in clinical and laboratory samples, sensitive and 
specific antibodies are required. Thus, the antigenic regions of ORF3, M and the 
entire E gene were amplified by PCR and ligated into a bacterial expression 
vector for expression and subsequent generation of antibodies in a mouse 
system. The identities of the cloned genes were confirmed by sequencing before 
 
 
 
 
xii 
being expressed in an in vitro bacterial system. Western Blots were used to 
identify the expression of the 41kDa, 42kDa and 34kDa GST-tagged viral proteins 
which were consistent with the bioinformatically predicted protein species.  
 
Verified fusion proteins were expressed in large quantities, quantified and 
concentrated for in vivo antibody production. Inoculation of 9 healthy, female 
Balb/C mice with the purified fusion proteins yielded high titers of polyclonal 
antibodies. Western Blotting was once again used to validate the production of 
the antibodies before their specificity was quantitatively measured using a 
modified competition ELISA. 
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CHAPTER 1 
Introduction 
The name "coronavirus" is derived from the Latin word “corona” meaning crown, 
as the viral morphology, under electron microscopy, appears to be crowned by a 
characteristic ring of small bulbous structures protruding (Spaan et al., 1988). The 
family Coronaviridae forms part of the order Nidovirales and consists of the 
genera Coronavirus (CoV) and Torovirus (Plant and Dinman, 2008). Both 
Coronaviruses and Toroviruses infect humans and animals and are mainly 
associated with enteric disease (Woode, 1994).  
 
The Coronavirus genus is subdivided into 3 groups based on their antigenic 
reactivity and genetic similarities (Zheng et al., 2006; Fielding et al., 2009). 
Whereas CoVs from groups 1 and 2 infect mammalian hosts, Group 3 CoVs have 
been found to infect avian hosts. Typical examples of Group 1 viruses include 
Canine coronavirus (CCV), Feline coronavirus (FeCoV), Porcine endemic 
diarrhea virus (PEDV) and Transmissable gastroenteritis Virus (TGEV). Bovine 
coronavirus (BCoV), Human coronavirus OC43 (HCoV-OC43), Mouse hepatitis 
virus (MHV), Porcine hemagglutinating encephalomyelitis virus (HEV), Rat 
coronavirus (RCV) and Human coronavirus HKU1 (Woo et al., 2005a) are 
examples of Group 2 coronaviruses. Group 3 coronaviruses include Infectious 
bronchitis virus (IBV) and Turkey coronavirus (Bluecombs disease virus) (Abdul-
Rasool and Fielding, 2010; Weiss and Martin, 2005). 
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Coronaviruses are capable of enormously varied pathogenicity and causing 
diseases that affect multiple organs through a variety of pathogenic mechanisms 
(McIntosh, 2005). Symptoms caused by coronaviruses are varied depending on 
the specific host species infected. In humans, these symptoms may include 
cough, rhinorrhoea, tachypnea, fever, abnormal breath sounds, hypoxia, severe 
atypical pneumonia, bronchiolitis, pharyngitis, dyspnea, desaturations, 
bronchospasm, vomiting, body rashes and wheezing chest (Weiss and Martin, 
2005). Animal coronaviruses can cause disease in organ systems other than the 
respiratory tract, such as the gastrointestinal system and the central nervous 
system (Pyrc et al., 2004). 
 
Epidemiology of Human Coronaviruses 
Human Coronaviruses (HCoVs) were first identified from clinical samples in 1965 
by Tyrrell and Bynoe and was shown to cause rhinitis or the common cold (Tyrrell 
and Bynoe, 1965). The isolated viruses were named HCoV-229E and HCoV-
OC43, were subsequently categorized as Group 1 and 2 coronaviruses, 
respectively (Pyrc et al., 2007a; Kahn, 2006; Woo et al., 2005b). 
 
Then, in early 2003 with the outbreak of severe acute respiratory syndrome 
(SARS), the causative agent was identified as a third HCoV (Drosten et al., 2003; 
Kuiken et al., 2003), which was classified a distant member of the Group 2 
coronaviruses (Gibbs et al., 2004; Snijder et al., 2003). SARS CoV, which causes 
acute respiratory failure, infected about 8000 people worldwide and had a 
mortality rate of about 10%.  Subsequent to this outbreak, two additional Human 
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Coronaviruses were identified; NL-63 from a 7-month-old child with an upper 
respiratory tract infection (van der Hoek et al., 2004) and HKU1 that was isolated 
from a 71-year-old man who presented with fever and cough (Woo et al., 2005a). 
With the exception of SARS CoV, the human coronaviruses continuously circulate 
in the population especially in children. 
 
Identification and Isolation of HCoV-NL-63 
A modified cDNA-AFLP method, VIDISCA, was used to identify HCoV-NL-63 from 
a nasopharyngeal aspirate taken from a 7-month-old child hospitalized with 
bronchiolitis, conjunctivitis, and fever (van der Hoek et al., 2004). While his chest 
X-ray showed clear signs of infection, the young boys’ aspirate tested negative for 
all known respiratory viruses. However, the aspirate still induced cytopathic 
effects (CPE) when inoculated onto monkey kidney cells. The previously unknown 
virus was later classified as a Group 1 coronavirus (van der Hoek et al., 2004; 
Pyrc et al., 2006b).  
 
Since its discovery, HCoV-NL-63 has been identified in many upper respiratory 
tract infection samples collected in different countries, especially from young 
children (van der Hoek et al., 2006; Chen et al., 2007). This virus has now been 
shown to have a world-wide distribution and has been isolated in places such as 
Australia (Arden et al., 2005), Canada (Bastein et al., 2005a), Japan (Suzuki et 
al., 2005), Belgium (Moës et al., 2005), USA (van der Hoek et al, 2005), France 
(Vabret et al., 2005), Germany (van der Hoek et al., 2005), China and Hong Kong 
(Chiu et al., 2005), Italy (Canducci et al., 2008), Korea (Choi et al., 2006), Taiwan 
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(Wu et al., 2008), Thailand (Dare et al., 2007), South Africa (Smuts et al., 2008), 
Switzerland (Kaiser et al., 2005) and in Sweden (Koetz et al., 2006), to name but 
a few.  
 
 
 
 
 
 
 
 
 
Figure 1: Schematic overview of the VIDISCA method  
Virus Discovery cDNA-AFLP (VIDISCA) utilizes virus isolated from cell culture supernatants of in vitro samples that 
displayed cytopathic effect (CPE) (de Souza Luna et al., 2008). Supernatants were then treated with DNase to digest 
cDNA before being used in a modified cDNA Amplified Fragment Length Polymorphism (AFLP) analysis. The modified 
AFLP uses the restriction enzyme digestion sites in the unknown DNA sequence to attach oligonucleotide adaptors, which 
are then used as primer binding sites for PCR and genomic sequencing (van der Hoek et al., 2004; Pyrc et al., 2008). 
  
Phylogeny and Toxicology of HCoV-NL-63 
Sequence analyses of the complete genome of HCoV-NL-63 reveal that the virus 
is more closely related to HCoV-229E than to the other human coronaviruses (van 
der Hoek et al., 2004) and that the genome has a mosaic structure. Phylogenetic 
analysis suggests that the current prevalent HCoV-NL-63 strain is the result of the 
genetic convergence of two sister coronavirus strains. This recombination event is 
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proposed to have resulted from a co-infection of a human host by a NL-63 strain – 
that diverged from a common HCoV-229E ancestor in the 11th century – and a 
prevalent HCoV-229E strain (Pryc et al., 2006; Arden et al., 2005; Chui et al., 
2005). 
 
Measuring the rate at which genetic divergence occurs in a particular species 
requires molecular clock analysis. This type of analysis assumes a constant rate 
of mutation within the species and is calculated based on available field data 
(Bromham and Penny, 2003). Analysis conducted on coronaviruses revealed an 
average substitution rate of 10-4 substitutions per year, per site (Sanchez et al., 
1992; Vijgen et al., 2005). The substitution rate from the coronaviral molecular 
clock analysis was applied to available sequence data from the S gene of HCoV-
229E (from known dates). Results of this analysis indicate that the most recent 
common ancestor between HCoV-229E and HCoV-NL-63 was indeed in the 11th 
century. This discovery also suggests that HCoVs have been present, and 
circulating, in the human race for hundreds of years (Moës et al., 2005; Vabret et 
al., 2005; Minosse et al., 2008; Pyrc et al., 2006b).  
 
Genomic Structure and Transcription Regulation of HCoV-NL-63 
The coronavirus family consists of single stranded, plus sense, polyadenylated 
RNA viruses (Pyrc et al., 2004). The viral genome is known to have helical 
genetic symmetry (Siddwell et al., 1983; Donaldson et al., 2008; Moës et al., 
2005). Since coronaviruses display no DNA stage during their replication cycle 
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they are classified as a Group IV virus family, according to the revised Baltimore 
scheme of viral classification.  
The coronaviruses have the largest genomes of known RNA viruses ranging in 
size from approximately 27 to 32kbp (Vabret et al., 2005). The large, unstable 
RNA genome, coupled with the lack of a proofreading replicase enzyme, results in 
frequent transcriptional errors, point mutations (Pyrc et al., 2006b) and the 
increased possibility of genetic recombination (Jia et al., 1995; Kusters et al., 
1990). The genome of HCoV-NL-63 consists of 27553 bases with a genomic 
organization 5’-ORF1a-ORF1b-S-ORF3-E-M-N-Poly-A tail-3’ (Figure 2 below). 
The RNA encodes for 7 putative open reading frames (ORFs) (Pryc et al., 2994), 
that are generated discontinuously using the negative sense strand to generate 
positive sense mRNAs (Pryc et al., 2007b). 
 
Coronaviruses generally express 3 categories of protein during new virion 
formation. The first category is expressed from ORFs 1a and 1b. These genes 
encode for the viral replicase enzymes that are required for viral assembly and 
the necessary activities for the transcription of negative stranded RNA, leader 
RNA, subgenomic mRNAs and progeny virion RNA as well as proteinases 
responsible for the cleavage of the polyprotein into functional products (Clementz 
et al., 2010). The structural proteins are encoded by ORFs found in the last 1/3 of 
the 3’-end of the RNA genome (Pyrc et al., 2004). These proteins are expressed 
from 4 subgenomic mRNAs (Pyrc et al., 2004) and include the spike (S), envelope 
(E), membrane (M) and nucleocapsid (N) proteins. These proteins are essential 
for virion particle formation (Pyrc et al., 2004). The final category of expressed 
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Figure 2: Genomic structure of HCoV-NL-63  
The genome is 27 553 nucleotides in length and is subdivided into replicase and structural genes. The arrow at 12 439 
nucleotides indicates the position of the –1 ribosomal frame-shift that is required to fully express ORF’s 1a and 1b. The 
figure also indicates the 5 subgenomic mRNA expressed by the structural and accessory genes, all with the same 5’ UTR. 
ORF 1a is further subdivided into Non-structural Proteins nsp1, nsp2, nsp3 and nsp4 with the largest non-structural protein, 
nsp3, encoding two papain-like proteases PLP1 and PLP2. 
 
proteins are the accessory proteins, whose genetic templates are dispersed 
among the structural genes. The functions of these proteins have not yet been 
clearly defined. Research, however, has indicated a possible involvement of these 
species-specific proteins in viral infectivity or modulation of pathogenesis in the 
natural host (de Haan et al., 2002; Haijema et al., 2004; Casais et al., 2005; 
Fielding and Suliman, 2009). 
 
 nsp1        nsp2                        nsp3                                 nsp4 
ORF 1a ORF 1b S ORF3 E M N 
12 439nt 
NL-63: 27553 nucleotides 
Replicase genes 
Structural genes 
5’ 3’ 
Poly A UTR  
(286nt) 
UTR 
(287nt) 
sg mRNA S 
sg mRNA ORF3 
sg mRNA E 
sg mRNA M 
sg mRNA N 
 
PLP1                  PLP2 
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Replicase Enzymes 1a and 1b 
The genetic template for the viral replicase enzymes is found on the first 2/3 of the 
RNA genome N-terminal. ORF1ab is expressed as a single protein that is later 
clearved by a protease (nsp3) encoded by the 5’ end of protein 1ab (Pyrc et al., 
2007c). A –1 frame-shift is required at position 12439nt for the ribosome to 
successfully express 1b gene. This frame-shift is facilitated by the formation of a 
putative elaborate hairpin pseudoknot (Namy et al., 2006), subsequently resulting 
in all expressed viral proteins having the same ~70nt transcription regulatory 
sequence at their N-terminus. 
 
In an in vitro system, non-structural proteins, nsp3 and nsp4, are detectable in 
peri-nuclear cellular regions, 24 hours post infection with NL-63 (Chen et al., 
2007). Chen and colleagues have also characterized two viral papain-like 
proteases, PLP1 and PLP2, which play a role in the processing of polyprotein 
1ab. PLP2 was also discovered to have deubiquitinating activity, but its function 
remains unclear. 
 
Nsp-3 and -5 proteins are coexpressed with polyprotein 1ab and have been 
shown to have papain-like and serine-like protease activity. Nsp-5 is regarded as 
the ‘main’ protease, however, and is responsible for processing, by means of 
cleavage, of most of the 1ab polyprotein (Ziebuhr, 2005). 
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Spike Protein  
The “crowned”-shape viral morphology observed is actually formed by the 
protruding viral spike (S) glycoproteins, which populate the surface of the virus 
and determine host-cell tropism (Li et al., 2005; Nal et al., 2005).  The spike 
protein mediates the viral attachment to specific cellular receptors on the host-cell 
surface and facilitates viral entry into the cell (Zheng et al., 2006; Cavanagh, 
1995). It is the largest of the structural proteins and, in the case of HCoV-NL-63, 
is seen to be 2380 amino acids in length (Pyrc et al., 2004).  
 
Coronavirus S-protein has been classified as a class I fusion glycoprotein 
consisting of a globular S1 region that recognizes the ACE2 receptor on human 
cells and the rod-like S2 region that mediates membrane fusion through a C-
terminal transmembrane fusion domain (Bosch et al., 2003). Also found in the NL-
63-S2 region is two heptad-repeat (HR) clusters which are larger than their 
correspondents found in other coronavirus species (Zheng et al., 2006; Pyrc et 
al., 2007c; Bosch et al., 2004).  
 
These HR repeat regions are highly conserved between Group II and III 
coronaviruses. Zheng et al. (2006) conducted proteolytic studies on the S2 fusion 
core and revealed a possible α-helical domain made up of a trimer of the HR 
sections N57 and C42. The finalized crystal structure of this region revealed high-
affinity conformations of interacting cross-sectional layers of six helices. Their 
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study concluded that the larger HR regions found in Group I coronaviruses, need 
to prime the S protein in order to activate the fusion conformation required during 
viral entry (Zheng et al., 2006).  
 
The N-terminal of the NL-63 S-protein possesses a 179 amino acid chain that has 
not been found in any other coronavirus. This unique section represents the most 
varied region of the NL-63 genome and is suspected to play a role in host immune 
system evasion (van der Hoek et al., 2006; Pyrc et al., 2007). Other research 
conducted on the S protein suggests that antibodies produced against the S have 
a neutralizing affect in vitro (Pyrc et al., 2006). Interaction between the spike and 
membrane proteins has been seen during viral assembly and prevents S from 
being transported to the host cells membrane surface during replication (Rottier 
and Rose, 1987; Opstelten et al., 1995). By preventing this intracellular 
processing and translocation of the S proteins to the infected cell surface, the 
membrane protein enables the virus to evade the hosts’ immune system.  
 
Open Reading Frame 3 
The ORF’s that encode for the accessory proteins of coronaviruses can be found 
distributed amongst the structural genes in the 3’ 1/3 of the RNA genome (Figure 
2). Group I HCoVs such as NL-63 and 229E both encode only one ORF whose 
genetic template can be found between the S and E genes (Franklin et al., 2006). 
Preliminary research conducted into the functions of the accessory proteins 
suggested that they were non-essential for viral growth in culture (Hodgson et al., 
2006; Casais et al., 2005; de Haan et al., 2002). Later research has however 
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indicated that ORF’s are required for in vivo infectivity and pathogenicity in the 
natural host (de Haan et al., 2002; Cavanagh et al., 2007; Netland et al., 2007; 
Haijema et al., 2004; Pewe et al., 2006).  
 
HCoV-NL-63 ORF3 is expressed from the fourth of the six subgenomic mRNAs 
produced by NL-63. This unique gene contains U-rich and A-poor pockets that 
suggested it to be a recently transferred gene from another genetic origin (Pyrc et 
al., 2004). NL-63 ORF3 has 3 trans-membrane regions, is N-glycosolated and is 
incorporated into the completed virion (Müller et al., 2010). In silico analysis of 
ORF3 predicts a 225 amino acid protein with a molecular weight of approximately 
26 kilodaltons (kDa) and is most homologues to HCoV-229E ORF4 (43% identity 
and 62% similarity). Fielding and Suliman (2009) hypothesize that ORF3 to be 
linked to pathogenesis in the natural host. 
 
Envelope Protein 
E is relatively under expressed in vitro and accounts of approximately 2% of the 
progeny proteins (Pyrc et al., 2004). This 78 amino acid protein has been singled 
out as being the only viral gene to not contain an upstream core transcription 
regulatory sequence (TRS). E does, however, contain its own sub-optimal 
variation of the TRS core sequence (AACUAUA) and a 13nt sequence identical to 
that of the leader sequence seen at the 5’ end of the genome. Pyrc et al. (2007), 
suggests that the annealing of this secondary leader sequence to the original 
leader sequence may compensate for the disturbed leader-TRS/body-TRS 
interaction.  
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Coronaviral E-protein has been shown to exhibit ion channel activity but the 
function of these channels has yet to be determined (Wilson et al., 2004). 
Interaction between the E and M proteins has been experimentally demonstrated 
(Godet et al., 1992; Yu et al., 1994; Lim and Liu, 2001; Maeda et al., 2001) and is 
required for the formation of virions with normal infectivity (Kuo and Masters, 
2003). Also, co-expression of coronavirus E and M proteins in vitro, results in the 
production of virus like particles (VLP’s) (de Haan et al., 1998; Ho et al., 2004).  
 
Membrane Protein  
Interaction of the coronaviral M-protein with the spike and envelope proteins has 
been well characterized (Godet et al., 1992; Yu et al., 1994; Lim and Liu, 2001; 
Rottier and Rose, 1987; Opstelten et al., 1995), as well as their interaction with 
the viral nucleocapsid proteins (Narayanan et al., 2000). With its triple-membrane-
spanning regions and its N-terminus endodomain, is evidently the most active 
viral protein expressed during virion formation (Armstrong et al., 1984; Rottier et 
al., 1986). It appears as though the progenic function of M is to incorporate the N 
protein into the newly formed virion during viral assembly (Narayanan et al., 2003; 
Narayanan et al., 2000; Narayanan and Makino, 2001).  
 
In the case of NL-63 M protein, this ~230 amino acid protein is the second most 
abundantly expressed viral protein, accounting for ~15% of the total expressed 
viral proteins during virion assembly (Pyrc et al., 2004). Similarly to NL-63 ORF3, 
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M is also seen to be a U-rich and A-poor region, suggesting a recent gene 
transfer from another genomic origin (Pyrc et al., 2004). 
Nucleocapsid Protein  
In comparison the other structural proteins, the coronavirus ~380 amino acid 
nucleocapsid proteins is not well characterized. It is however documented to be 
the most abundantly expressed viral protein, ~74% of the progeny proteins (Pyrc 
et al., 2004). Also, coronavirus nucleocapsid proteins have been shown to interact 
with co-expressed N proteins, forming dimers (Yu et al., 2005). Studies have 
shown interactions between coronaviral N-proteins and all sub-genomic and 
genomic RNAs (Baric et al., 1988; Stohlman et al., 1988). Exploration into HCoV-
NL-63 N-protein-RNA interaction, lead to the discovery of the N-terminus RNA 
chaperone motif, which facilitates the movement of the genomic RNA into the new 
virion (Zúñiga et al., 2006). 
 
Viral Entry and Replication 
As mentioned earlier, the genomic order of the HCoV-NL-63 genome is 1ab-S-
ORF3-E-M-N (Figure 2). The 5’ 2/3rds (i.e.: genes 1a and 1b) of the genome 
encodes two polyproteins that contain all the enzymes required for RNA 
replication. These polyproteins are transcribed from genes 1a and 1b and require 
a –1 ribosomal frame shift (Figure 2) for the successful expression of gene 1b 
(Herold et al., 1993; Giedroc et al., 2000). The polyprotein that is produced by the 
ribosome undergoes a catalytic cleavage by the viral papain-like proteinase and a 
chymotrypsin-like proteinase to produce proteins 1a and 1b (Chen et al., 2007).  
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A protein is transcribed from the ORF1. 
 
Protein 1 
The RNA forms a pseudo hairpin knot and the next ORF is translated. 
Protein 2 
 
RNA polymerase 
 
 
Leader / UTR 
 
ORF 1 
 
 
ORF 2 
 
Genomic RNA 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Formation of the Pseudo Hairpin Knot  
The figure above graphically depicts the formation of the pseudo hairpin knot employed by coronaviruses during viral 
replication. This genomic conformation results in all expressed viral proteins having the same leader sequence. 
 
Coronaviruses replicate by using the host-cell ribosomes and metabolites to 
produce multiple copies of the infecting virion in the cytoplasm (Brockway et al., 
2003; Siddwell et al., 1983; Konings et al., 1988; Bond et al., 1979). Genomic 
replication generally follows the uncoating of the viral genome inside the host cell 
cytoplasm (Siddwell et al., 1983). The polyadenylated, positive sense RNA is read 
directly by the host ribosomes as mRNA and the replicase genes 1a and 1b are 
translated into the viral RNA dependant RNA polymerase and a viral protease 
(Ziebuhr et al., 2000; Sawicki et al., 2007). These enzymes are then employed by 
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the virus to produce a multitude of viral progeny in a microenvironment 
established in the host-cell’s cytoplasm (Brockway et al., 2003; Siddwell et al., 
1983; Konings et al., 1988; Bond et al., 1979).  
 
The N protein is found to be the most abundant viral protein present during the 
replication cycle (Pyrc et al., 2004). This is followed by M, ORF3, S and finally E. 
The phenomenon observed in coronavirus replication indicates that the further 
away from the leader sequence the gene lies, the more it is transcribed. This 
theory holds true for all expressed HCoV-NL-63 proteins with the exclusion of the 
E protein, which relatively underexpressed (Pyrc et al., 2004).  
 
The suggested explanation for this phenomenon is that the structural genes are 
transcribed from subgenomic mRNA during replication. Researchers suggest the 
formation of a pseudo hairpin knot to be responsible for each expressed protein 
having the same leader sequence (Herold et al., 1993; Giedroc et al., 2000). 
 
Coronaviruses have a lysogenic life-cycle meaning that the virus can cause 
degenerative effects within a host cell without causing its death. These effects 
generally result in the rounding up of the infected host cell or detachment of the 
infected cell from the surrounding tissue. These symptoms are collectively called 
the cytopathic effects (Pyrc et al., 2006; Herzog et al., 2008). Released virions 
can be passed to other sites within the body by traveling through the bloodstream 
or even between hosts through direct contact. More commonly, transmission 
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occurs through contact with infected bodily fluids such as sputin and saliva 
(Bridges et al., 2003). 
The virus infects the new host via the respiratory tract and binds to the upper 
respiratory tract epithelium. Next, the virus gains entry into the susceptible 
epithelium cells through the use of the ACE 2 surface receptor. This entry into 
susceptible host cells is mediated by the spike protein, which is found on the 
virion envelope surface (Cavanagh, 1995). Once inside the cell, the virus induces 
the host cell to begin manufacturing the proteins necessary for virus reproduction. 
As well as proteins production, the virus must also direct the replication of new 
viral genomes. Coronaviral replication takes place with the use of nested ends, 
meaning that the leader sequence (found just before the start codon for of every 
protein) remains constant with every protein that is transcribed from genomic 
RNA. This is achieved by the genomic RNA bending and forming a loop, which 
moves the leader sequence adjacent to the start codon of the next ORF that is to 
be transcribed (Herold et al., 1993; Giedroc et al., 2000). As a result, each gene 
that is transcribed has the same leader sequence.  
 
Seasonal Incidence and Prevalence 
To date, HCoV-NL-63 has been shown to have a worldwide distribution. Initially, 
the virus was observed primarily in the winter seasons in countries with temperate 
climates. On the other hand, countries with extreme weather, like Canada, have 
also shown virus activity around January to March, although milder symptoms 
were reported (Bastein et al., 2005a). Also, seasonal variations have been 
reported in China where infection with HCoV-NL-63 appeared mainly in spring 
 
 
 
 
CHAPTER 1________________________________________________________________ 
Page 17 of 109 
and summer (Chiu et al., 2005). Additionally, Wu et al. (2007) reported that the 
virus is detectable in the autumn season in Taiwan (Wu et al., 2008). A more 
recent study of coronaviruses in Thailand though, did not show any seasonal 
predilection (Dare et al., 2007). Collectively, results show that the virus has no 
predilection to a particular season and is not affected by temperature variations as 
infections can occur throughout the year.  
 
Human coronaviruses are known to be the etiology of a significant number of 
hospitalizations of children under the age of 18, the elderly and the 
immunocompromised. A one-year study conducted in Hong Kong (Chiu et al., 
2005) revealed the presence of human coronaviruses in 4.4% of all children 
hospitalized with respiratory tract infections, of which NL-63 was seen to be the 
most abundant (2.6%). Another respiratory study carried out in Japan revealed 
the presence of NL-63 in 1.2% of the 419 samples that tested negative for any 
other respiratory viruses (Suzuki et al., 2005). Ebihara et al. (2005) also reported 
the incidence of NL-63 in 2.5% of 118 nasopharyngeal swab samples collected 
from kids under the age of two in Germany.  
 
High respiratory coronavirus incidences were also noted abroad in the European 
regions. Documented incidences include studies conducted in France (Vabret et 
al., 2005) and Belgium (Moës et al., 2005) which positively validated the presence 
of HCoV-NL-63 in 9.3% of 300 samples and 2.5% of 279 samples, respectively. 
van der Hoek et al. (2005) discovered 5.2% incidence rate of NL-63 in 949 
samples that they rechecked from a previous survey conducted by Forster et al. 
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(2004), to evaluate lower respiratory tract infections in children under the age of 3, 
in Germany. 
In Australia, a respiratory survey study was conducted on 543 patients with 
respiratory symptoms in Melbourne (Lambert et al., 2007). Eighteen of those 
patients tested positive for HCoV-NL-63. In the west, 3.6% of 525 patient samples 
tested by Bastein and colleagues in Canada (2005), were positive for NL-63 in 
comparison to the 8.8% of the 895 patient samples tested by Esper et al. in the 
Unites States (2005). 
 
Co-infections with NL-63  
Superinfections of NL-63 with other respiratory viruses appear to be quite 
common, often resulting in patient hospitalization due to the severity of these 
infections (Chui et al., 2005; Minosse et al., 2008; Dare et al., 2007; Wu et al., 
2008; Canducci et al., 2008; van der Hoek et al., 2005; Lambert et al., 2007; 
Kaiser et al., 2005; Yoo at al., 2007). The most common respiratory co-infection 
observed in children under 3 years of age, is a combination of Respiratory 
Syncytial Virus-A (RSV-A) and NL-63, whose seasonality patterns seem to 
overlap (van der Hoek et al., 2005). Other co-infecting agents include other 
human coronaviruses, influenza A virus, parainfluenza virus (PIV) and human 
metapneumovirus (hMPV). Smuts and Hardie (2006) reported one incident of a 
bocavirus/NL-63 co-infection from a study screening 341 nasopharyngeal and 
bronchoalveolar specimens of hospitalized children in South Africa.  
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The HCoV-NL-63 viral load of patients infected with HCoV-NL-63 only is slightly 
higher than patients co-infected with NL-63 and other respiratory viruses (van der 
Hoek et al., 2005). Professor Lia van der Hoek and colleagues proposed four 
theories to explain this phenomenon (2005):  
1. NL-63 might be the primary infecting agent, which lowers the host’s 
immunity, allowing for opportunistic respiratory infections. By the time 
diagnostic tests are done on the patient, the NL-63 infection has already 
been subdued.  
2. The two infecting agents may be competing for receptor binding or viable 
cells in the host organs.  
3. The secondary infection hyper activates the host’s innate immune system 
causing it to inhibit NL-63 replication.  
4. NL-63 exists as a prolonged or persistent infection resulting in low-level of 
virus detection. 
 
Clinical Presentation 
NL-63 has been identified in both upper and lower respiratory tract infections and 
the clinical presentation of these infections mimics those of seen in HCoV 229E 
and OC43 infections (Vabret et al., 2008). Commonly, mild symptoms are 
observed in most patients who contract upper respiratory infections of NL-63. 
These symptoms generally include fever, cough and rhinorrhoea.  
 
Lower respiratory tract infections with NL-63 display more severe symptoms such 
as bronchiolitis and inflammation of the bronchiole basal membranes. Although 
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research conducted in China did not associate HCoV-NL-63 with bronchiolitis 
(Chiu et al., 2005), other research groups have observed these severe respiratory 
symptoms (Arden et al., 2005; Ebihara et al., 2005; Bastien et al., 2005). Croup, a 
disease seen mostly is children, which presents with pharangitis, sore throat and 
hoarseness of voice, has also been associated with NL-63 by at least two 
research groups (Chiu et al., 2005; van der Hoek et at., 2005).  
 
The majority of NL-63 patients who present at hospitals or clinics are children and 
their recorded symptoms are based mainly on parental observation, which may 
prove to be somewhat uneducated. The lack of informed observation results in 
not all possible symptoms of NL-63 infections being identified. Patients examined 
for NL-63 infections on arrival at a hospital are generally admitted for respiratory 
symptoms. Hence, possible NL-63 infections of other organ systems might never 
be identified. 
 
Laboratory Diagnosis and Detection  
Diagnoses of HCoV-NL-63 infections are difficult to distinguish from the many 
other respiratory viruses that are known to co-infect with NL-63. Incorrect 
treatment of these misdiagnosed patients often results in increased health care 
expenses and increased chance of disease spread (Fox, 2007). Two methods 
exist for NL-63 detection from clinical samples: Detection of viral RNA and 
serological detection of NL-63 specific proteins. 
 
Detection of viral RNA  
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Due to its high specificity and sensitivity, the gold standard diagnostic test for the 
detection of coronavirus RNA is the reverse transcriptase polymerase chain 
reaction (Fielding and Tan, 2007). RT-PCR and other nucleic-acid-based tests are 
also seen as the preferred methods for detecting NL-63 from clinical samples. 
ORF1ab, N and S genes are generally the targets for these nuclear diagnostic 
tests (Arden et al., 2005; Chiu et al., 2005; Moës et al. 2005; Minosse et al., 2008; 
Bastien et al., 2005; Dare et al., 2007).  
 
In vitro coronavirus studies indicate that N is the most abundantly present viral 
protein in infected cells, which theoretically makes it a perfect target for PCR 
assays. This theory has however not been clearly proven in clinical studies 
(Cheng et al., 2007). One of the main advantages of RT-PCR is that it can be 
performed on both fresh and frozen nasopharyngeal aspirate samples and viral 
culture can be used as confirmation of NL-63 infection (Kistler et al., 2007; 
Shirmizu et al., 2005).  
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Scope of this thesis 
The future of drug development against RNA viruses is expected to have a 
significant indirect and direct impact on human health-related quality of life. RNA 
viruses include in excess of 350 different major human pathogens and are 
responsible for many emerging and reemerging diseases. These pathogens are 
responsible for not only very frequent benign diseases (which nonetheless have a 
huge economic impact, vide infra) but also for millions of deaths each year in both 
industrialized and developing countries. Even though many treatments exist for 
infections caused by DNA-based viruses, few efficient antiviral drugs against RNA 
viruses have been developed.  
 
In the United States, the common cold leads to 75 to 100 million clinical visits 
yearly at a conservative cost estimate of $7.7 billion per annum. Americans spend 
$2.9 billion on over-the-counter medicine and another $400 million on prescription 
medicines for relief of symptoms (Garibaldi, 1985; Fendrick et al., 2003). More 
than 30% of patients who consulted a physician received an antibiotic 
prescription, which has implications for antibiotic resistance from misuse of such 
drugs (Fendrick et al., 2003). Also, an estimated 22 to 189 million school days are 
missed annually due to the common cold which resulted in parents missing about 
126 million workdays to stay home to care for their children. When added to the 
150 million workdays missed by employees suffering from the common cold, the 
total economic impact of cold-related work loss exceeds $20 billion per year 
(Garibaldi, 1985; Fendrick et al., 2003). Clearly, the development of drugs against 
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RNA virus infections is expected to have a significant impact on human health-
related quality of life.  
 
Among the most significant viral infectious agents are coronaviruses (10- 15% of 
all common colds in the world). Coronaviruses are not well characterized. Until the 
discovery of the severe acute respiratory syndrome coronavirus (SARS-CoV) in 
2003 (Drosten et al, 2003), coronaviruses were known to cause mainly mild 
respiratory infections in the general populace and various complications in 
immunocompromised patients (Hsueh and Yang, 2003). This changed after the 
outbreak of SARS-CoV. Since the identification of SARS-HCoV two additional 
human coronaviruses have been identified from clinical samples. Although these 
newly identified coronaviruses are usually not lethal, both of these causes 
respiratory and other infections that results in economic loss. 
 
For studying pathogenicity and replication of viruses in the host or animal models, 
it is essential to generate viral protein-specific antibodies. Also, the genome of 
HCoV-NL-63 is not well characterized and the functions of the proteins 
transcribed by its genome, with a few exceptions, are not understood. Therefore 
the generation of specific and sensitive antibodies would allow the study of the 
different viral proteins in vitro as well as in vivo. Therefore, the main objectives 
of this thesis are: 
1. RT-PCR amplification of the HCoV-NL-63 genes encoding for the structural 
proteins M and E and the accessory (group-specific) protein ORF3 from 
viral RNA.  
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2. Cloning of the amplification products into vectors for expression in a 
bacterial system. 
3. Expression and purification of the viral-fusion proteins. 
4. Generation of polyclonal antibodies specific to the viral-fusion proteins. 
5. Validation of the specificity and sensitivity of the antibodies.  
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CHAPTER 2 
 
Methods and Materials 
Bioinformatic Analysis of M, E and ORF3 
In silico analysis of HCoV-NL-63 proteins M, E and ORF3 was done with 
Invitrogen’s peptide selector application, which mathematically predicts and 
graphically displays the most antigenic region of the queried amino acid sequence 
(http://peptideselect.invitrogen.com/peptide/). This application calculates the 
position of the most probable antigenic regions by taking into account the specific 
amino acid charge, possible post-translational modification and theoretical protein 
tertiary and quaternary structure and represents it in a graphical presentation. In 
this study, HCoV-NL-63 ORF3 and M proteins were calculated to contain three 
theoretical membrane-spanning regions in their 5’ halves. Thus, the antigenic 3’ 
halves were selected to be analyzed experimentally. These 3’ regions will be 
referred to as ∆N regions from here on. The E protein however, contained no 
putative membrane spanning regions.  
 
cDNA Synthesis 
HCoV-NL-63 RNA (a kind gift from Prof. L van der Hoek, Holland) was used as 
template to synthesize 1st strand cDNA. RNA was extracted from a fifth-passage 
virus (strain Amsterdam 1) obtained from a clinical sample. Reverse transcription 
was carried out using a mixture of 2µl RNA template (108-109 copies/ml), 1µl of 
Oligo (dT)15 primer (100µM stock), 1× incubation buffer, 2µl of dNTP mix (10mM 
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stock), 20U RNasin® Ribonuclease inhibitor, 15U of AMV Reverse Transcriptase 
and 4µl MgCl2 (25 mM) and was made up to a total volume of 20 µl in nuclease-
free water, according to the manufacturer’s specifications (Promega). The 
reaction was heated at 42ºC for 60 min, 95ºC for 5 min and then cooled to 0ºC for 
5 min to deactivate the enzyme. 
 
Primer Design and Gene Amplification 
PCR primers were designed to amplify the putative antigenic regions of ORF3 
and M and the entire E gene and have an appropriate melting temperature and 
restriction sites for ligation into the expression vector. Briefly, all forward primers 
designed included a 5’ restriction enzyme recognition site for Sgf I (for the in-
frame, unidirectional ligation of the amplified gene into the bacterial expression 
vector) and 20 to 25 nucleotides identical to the 5’ end of the target gene. All 
reverse primers were created to include a Pme I restriction enzyme recognition 
site and a 20 to 25-nucleotide sequence, which was the reverse complement of 
the 3’ end of the target gene (Table 1). Forward and reverse primers were 
engineered to have a melting temperature between 55˚C and 65˚C. 
 
100µM of the designed primers were used to amplify the hydrophilic portions of 
both the M (nt 300-681) and ORF3 (nt 330-678) genes and the entire E gene from 
the generated 1st cDNA. PCR reactions were carried out in total volume of 25 µl 
using 2.5U of GoTaq DNA Polymerase, 0.5µl dNTP mix (10mM stock), 2µl MgCl2 
(25mM stock), 2.5µl 10X MgCl2-free GoTaq Flexi buffer and 2µl cDNA according 
to the manufacturer’s specifications (Promega).  
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Amplification was carried out in a Multi Gene™ II Thermocycler (LabNet) using 
the following optimized conditions: Initial denaturation at 95ºC for 3 min, followed 
by 30 cycles of: denaturation at 95ºC (45 sec), annealing at 50ºC (60 sec) and 
elongation at 72ºC (60 sec). A final extension step at 72ºC for 15min was 
included, before a final hold at 4ºC.  
Table 1: Primers used for amplification of HCoV NL-63 ORF3ΔN, MΔN and E genes 
Gene    Primer Sequence 
ORF3ΔN-Forward 5’-TGCGGCGATCGCCAGACTTTGGCGCCGTGTTAAAAC-‘3 
ORF3ΔN-Reverse 5’-TGTGGTTTAAACTTAGATTAAATGAAGCAACTTCTC-3’ 
MΔN-Forward 5’-GGCCGCGATCGCCGGCTATTATGCCTATCTCTATAAAAA-3’ 
MΔN-Reverse 5’-GCCGTTTAAACTCAATTAATCGAAGGAACATCTTCGTA-3’ 
E-Forward                5’-GCGCGCGATCGCCATGTTCCTTCGATTAATTG-3’ 
E-Reverse                5’-GCGCGTTTAAACTTAGACATTTAGTACTTCAGC-3’ 
N.B.: Sgf I cut sites are underlined and Pme I cut sites are bolded 
 
On completion of the PCR, 5μl of a 6X blue/orange DNA loading-dye (0.03% (v/v) 
bromophenol blue, 0.03% (v/v) xylene cyanol FF, 0.4% (v/v) orange G, 15% (v/v) 
Ficoll 400, 10mM Tris-HCl (pH 7.5) and 50mM EDTA (pH 8.0)) was added to each 
sample before they were loaded into a 1% (w/v) agarose gel (0.1% w/v Ethidium 
Bromide). 5μl of a 100bp DNA marker (Promega) was also loaded onto the gel 
before the amplified gene products were separated by electrophoresis at 90V. 
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Gel Purification 
Amplicons were gel-purified with the Wizard SV Gel and PCR Clean-Up system 
(Promega). Amplification products were excised from the agarose gel under short-
wave length UV illumination and transferred to a pre-weighed, sterile 1ml 
Eppendorf tube to determine the weight of the gel piece. The gel was then 
solubilised by adding an equal volume of Membrane Binding solution (4.5M 
guanidine isothiocyanate and 0.5M potassium acetate (pH 5.0)), followed by 
incubation at 60ºC with constant vortexing to ensure complete dissolution. Next, 
the dissolved DNA was gravity filtered through a positively charged, nuclearpore 
membrane by centrifugation. This membrane bound the DNA on the basis of its 
negative charge. The membrane was then washed with 1200µl of Membrane 
Wash solution (10mM potassium acetate (pH 5.0), 80% (v/v) ethanol and 16.7μM 
EDTA (pH 8.0)) to dissolve all unwanted salts and purify the bound DNA. Bound 
DNA was eluted in 30µl of nuclease-free water. 
 
Ligation into Sequencing Vector and Transformation into JM109 cells  
pGEM T-Easy was the selected sequencing vector to verify the inserted viral 
genes (Figure 37 in Appendix). The vector contains various characteristics that 
were deemed desirable for this stage of the study, including: 
o A Lac-Z operon that encodes the enzyme ß-galactosidase, which is able to 
digest the substrate X-gal in the presents of IPTG (Isopropyl-beta-D-
thiogalactopyranoside), producing a blue dye which in turn produces a blue 
colony when plated. During a successful ligation, this gene is disrupted, 
which results in the growth of a white colony. 
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o M13 sequencing primer-binding site for cost effective sequencing of vector-
insert constructs. 
o Ampicillin resistance gene to which allows for the growth of successfully 
transformed bacterium on ampicillin containing selective, semisolid media. 
o And 5’ and 3’ T-overhangs that allow for the easy ligation of adenosine 
appended PCR products into the vector at the multiple cloning site.  
 
Ligation into the pGEM T-Easy vector was achieved by incubating 6 units of T4 
DNA Ligase, 50ng of cut pGEM T-Easy vector and 7.5μl of the purified PCR 
products at 4˚C overnight in reaction buffer (300mM Tris-HCl (pH 7.8 at 25°C), 
100mM MgCl2, 100mM Dithiothreitol and 10mM ATP). The resultant constructs 
were transformed into JM109 chemically competent E. coli cells by incubating 5μl 
of the constructs with 50μl of the recently thawed competent cells at 42˚C for 
45sec. The transformation reaction was then placed on ice for 2min before the 
cells were allowed to recover for 1 hour at 37˚C in 1ml of antibiotic-free LB liquid 
media.  
 
Each liter of LB liquid media (broth) used in this experiment consisted of 10g 
Bacto-tryptone, 5g yeast extract and 10g Sodium Chloride. 800ml of distilled 
water was then added to the dry ingredients before being thoroughly mixed and 
pH adjusted to 7.5 using Sodium Hydroxide. Finally, the media volume was 
adjusted to 1L before being autoclave sterilized.   
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Control measures taken during the transformation procedure included a positive 
transformation control (pGEM-3Z vector (Figure 38 in Appendix) to measure 
transformation efficiency), a background control (Ligated vector without viral 
insert) and 50μl of JM109 competent cells to verify the efficacy of the Ampicillin 
(100μg/μl) in the plating-media. Also included in the semisolid media was 1mM of 
the Lac-Z operon inducer (IPTG) and 50µg/ml of the ß-galactosidase substrate 
(X-gal) to facilitate blue/white colony selection.   
 
Colony Picking and Plasmid Extraction  
After a 14-hour incubation at 37˚C, 4 white colonies were picked from each of the 
experimental plates using a sterile pipette tip, and inoculated into 10ml of LB 
media containing 100μg/ml Ampicillin. These inoculated broths were then 
incubated at 37˚C overnight with continuous shaking (150rpm). The now slightly 
turbid cultures displayed atypical optical densities of ~0.3 (600nm) in comparison 
to the expected ~2.0 absorbance (600nm). Culture volumes were thus adjusted 
by 4 fold to comply with the optimal biomass input requirements, as suggested by 
the supplier (Promega).  
 
In compensation for the low culture concentrations observed, 20ml of the 
inoculated cultures were centrifuged at 2800rpm to pellet the suspended cells 
before being resuspended in 250μl of cell resuspension solution (50mM Tris-HCl 
(pH 7.5), 10mM EDTA and 100µg/ml RNase A). The cells were then lysed in 
350μl cell lysis solution (0.2M NaOH and 1% (w/v) SDS) and 10μl alkaline 
protease before 450µl of Neutralizing reagent (1.32M potassium acetate (pH 4.8)) 
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was added. The cell debris was pelleted at 16000xg and the cell lysates were 
filtered through a nuclearpore membrane at 16000xg to bind the negatively 
charged DNA and elute unwanted compounds. 1ml of membrane wash solution 
(80mM potassium acetate, 8.3mM Tris-HCl (pH 7.5) and 40µM EDTA) purified the 
DNA by filtering it through the membrane at 16000xg and removing all unwanted 
salts. The plasmid construct was then eluted in 30μl of nuclease free water and 
placed on ice until further use. 10μl of the extracted plasmid DNA products were 
sent to Inqaba Biotech (Pretoria, SA) for the purpose of gene sequencing. 
 
Sgf1 and Pme1 Restriction Digest of Constructs 
2µl of the 10X concentrated Sgf I and Pme I enzymes blend (Promega) was used 
to digest 10μl of the various isolated pGEM-viral-insert constructs. The reaction 
was then incubated at 37˚C for 2Hrs in a 1X enzyme digest buffer (50mM Tris-HCl 
(pH 7.9 at 37°C), 250mM NaCl, 50mM MgCl2, 5mM Dithiothreitol and 0.5mg/ml 
acetylated BSA) before it was heated to 65˚C to deactivate the restriction 
enzymes. The samples were separated on a 1% (w/v) agarose gel at 90 V before 
the genes of interest were gel purified as previously described. The products were 
then eluted in 30μl of nuclease free water. 
 
Ligation into Bacterial Expression Vector 
Subsequently, 5μl of the eluted ‘sticky-ended’ viral genes were ligated with 50ng 
of the bacterial expression vector, pFLEXI-GST (pFN2A Glutathione-S-
transferase tagged) (Figure 39 in Appendix). The overnight ligation took place at 
4˚C with the use of 12 units of T4 DNA ligase enzyme in 1X reaction buffer 
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(300mM Tris-HCl (pH 7.8 at 25°C), 100mM MgCl2, 100mM Dithiothreitol and 
10mM ATP). The new expression constructs were transformed into 50μl of KRX 
chemically competent E. coli cells (Promega) at 42°C for 45 sec before being 
incubated on ice for 2 min. KRX was selected as the bacterial expression cell line 
due to the absents of genomic proteases expressed from the bacterial genome. 
 
GST-tagged construct-containing KRX cells were spread-plated on semisolid LB-
agar containing 100μg/ml Ampicillin. Overnight incubation of the plated samples 
at 37°C, resulted in the appearance multiple white colonies containing the 
inserted viral-gene expression constructs. 4 single colonies were selected from 
each sample plate and inoculated into 10ml of LB broth with the appropriate 
antibiotic (50µg/ml of Ampicillin). The cultures incubated at 37°C, overnight, with 
constant shaking (150rpm). 
 
Glycerol Stocks and Gene Insert Validation 
Glycerol stocks were made by homogenizing 250μl of the incubated cultures with 
750μl molecular grade glycerol and storing them at –80˚C. A scraping of each 
glycerol stock was inoculated into the 10ml of LB broth containing the Ampicillin. 
Another cell scraping of each sample was inoculated into 10ml of broth containing 
an antibiotic to which the bacteria were susceptible (30µg/ml of Kanamycin was 
used for GST vectors) in order to validate the efficacy of the antibiotic resistant 
gene found in each vector. 
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Plasmid DNA was extracted from the first group of overnight cultures and 
restriction enzyme digested using Sgf I and Pme I to validate the presence of the 
viral insert in each construct (as previously described). Validated glycerol stocks 
were stored at –80˚C. 
Pilot Study: Expression of MΔN-GST Fusion Protein  
An overnight culture of MΔN-GST was diluted 1:100 in 250ml fresh LB media 
containing 50μg/ml Ampicillin (for GST vectors). The inoculated culture was 
incubated at 37˚C with continuous shaking (150rpm) until it reached an optical 
density of ~0.2 (600nm). Once optimal density (OD of 0.2 at 600nm) was reached, 
the culture was titrated with 0.1% L-Rhamnose (w/v) to induce protein expression. 
Every 2Hrs post induction a 10ml sample of the culture was collected and stored 
at 4˚C until needed. On completion of the incubation period, the collected 10ml 
samples were centrifuged at 2800rpm to pellet the bacteria. 
 
The pellets were resuspended in 3.6ml fresh LB media before adding 400μl of 
10X concentrate FastBreak Cell Lysis reagent (Promega) and vortexing. Samples 
were incubated at room temperature for 30min with gentle shaking before being 
centrifuged at 5000xg to pellet cell debris. 200μl of the cell lysates were extracted 
and diluted 1:1 in SDS Laemmli’s loading buffer (4% (w/v) SDS, 20% (v/v) 
Glycerol, 10% (v/v) ß-mercaptoethanol, 0.004% (v/v) Bromphenol blue and 
0.125M Tris HCL (Fluka)) preceding boiling at 95˚C for 3min, in a dry bath. The 
expressed proteins were separated on a 15% (w/v) polyacrylamide SDS-PAGE 
(at 20mA) and Coomassie stained to visualize the expressed proteins and 
substantiate when optimal protein expression levels were achieved. 
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Expression of Viral GST Fusion Proteins by Autoinduction 
Various modifications were attempted to reduce the latency of protein expression 
observed in the standard protein expression. One of these attempts was to modify 
the expression broth by adding 0.05% filter sterilized Glucose (v/v) and 0.1% L-
Rhamnose (w/v), to assist the cultures in reaching optimum biomass before 
expression was induced. This autoinduction protocol was described by the 
manufacturer (Promega, USA) and was adopted as the preferred expression 
protocol used for the remainder of this body of work.  
 
Overnight starter cultures (Glycerol stock scraping inoculated into 10ml LB broth 
with 50µl/ml Ampicillin.) were diluted 1:100 in 250ml fresh LB media containing 
Ampicillin (50μg/ml), 0.05% filter-sterilized Glucose (w/v) and 0.1% L-Rhamnose 
(w/v). Inoculated cultures were incubated at 37˚C for 24Hrs with continuous 
shaking (150rpm). Every 2Hrs a 10ml sample of the culture was collected and 
stored at 4°C until needed. On completion of the incubation period, the collected 
samples were centrifuged at 2800rpm to pellet the bacterial cells.  
 
The pellets were resuspended in 3.6ml fresh LB media before adding 400μl of 
10X concentrate FastBreak Cell Lysis reagent (Promega) and vortexing. Samples 
were incubated at room temperature for 30min with gentle shaking before being 
centrifuged at 5000xg to pellet cell debris. 200μl of the cell lysates were extracted 
and the protein concentration quantified using a Bradford total protein assay 
(BioRad). 
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Expressed Protein Quantification 
The Bradford assay required 5μl of the cell lysates to be added to 250μl Bradford 
1X dye reagent (at room temperature) in a 96 well clear bottom plate. Absorbance 
was read at 590nm and the concentration of the six samples calculated by 
substituting their specific OD’s into the equation of the standard curve. The 
samples were divided into 30mg aliquots and diluted 1:1 in SDS Laemmli’s 
loading buffer (4% (w/v) SDS, 20% (v/v) Glycerol, 10% (v/v) ß-mercaptoethanol, 
0.004% (v/v) Bromphenol blue and 0.125M Tris HCL (Fluka)) preceding boiling at 
95˚C for 3min, in a dry bath. 
 
Validation of GST Fusion Protein Expression  
15mg of each of the three GST-fusion viral proteins were separate by SDS-PAGE 
gel electrophoresis at 20mA/gel for 74min. On completion one of the SDS-PAGE 
gels (10cm X 8cm) was visualized by soaking it in Coomassie Blue Stain (45% 
(v/v) Methanol, 10% (v/v) Glacial acetic acid, 45% (v/v) distilled water and 3g/l 
Coomassie Brilliant Blue R250 powder (Fluka)) overnight, with gentle rocking, 
followed by destaining in Coomassie Destain solution (30% (v/v) Methanol, 10% 
(v/v) Glacial acetic acid and (v/v) 60% Distilled water) for 12Hrs with rocking.  
 
Western Blot analysis  
The remaining duplicate SDS-PAGE gel was transferred by Western Blot onto 
PVDF (Polyvinylidene Fluoride) membrane (BioTrace) in a submersion, transfer 
system (Hoofer: Mighty Small Transfer) at 100V, for 90min, with the use of a 
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cooling system. The resultant membrane was soaked in Ponceau S (0.1% (w/v) 
Ponceau S powder (BioLab), 5% (v/v) acetic supplemented to 1L with distilled 
water) to verify protein transfer and for consistent protein-concentration loading 
verification, before being blocked in blocking solution (3% (w/v) fat free powder 
milk (BioRad) in phosphate buffered saline (PBS) containing 0.05% (v/v) Tween-
20). Once blocked, the blot was exposed to a 1:5000 dilution of rabbit anti-GST 
primary antibody (Santa Cruz Biotechnology), in 3% the milk, overnight at 4˚C 
with continuous rolling. 
 
Following the overnight incubation, the blot was washed three times in 1X PBS 
containing 0.05% (v/v) Tween-20 for 15min per wash. The secondary antibody, 
goat anti-rabbit conjugated with Horse Radish Peroxidase (Santa Cruz 
Biotechnology), was diluted 1:5000 in the 3% milk and exposed to the blot for one 
hour at room temperature on a roller mixer. The blot was once again washed in 
the PBS solution before being exposed to the HRP chromogenic substrate (KPL) 
at room temperature for ~10min. Blots were photographed using a Canon (G6 
Powershot) camera on a white background. 
 
Antigen Generation 
Protein production now validated, the viral GST-fusion proteins were once again 
expressed in KRX bacteria under the influence of the inducer L-Rhamnose. The 
75ml cultures (LB broth + 100μg/ml Ampicillin) were then pelleted at 5000rpm for 
10min before being reconstituted in 36ml of saline (0.7% (w/v) NaCl), bringing 
culture concentration closer to the required absorbance of 2 (OD 600nm). Next, 
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4ml of the 10X FastBreak bacterial cell lysis solution (Promega) was added to the 
cultures, which were incubated at R/T for 30min, with rocking.  
 
The lysed bacteria were centrifuged at 8000rpm to pellet cell debris and isolate 
the soluble cytoplasmic proteins. The lysates containing the expressed proteins 
were subsequently gravity filtered through 10mg-capacity, GST-affinity, agarose-
based column (Thermo Scientific) to isolate the expressed GST-fusion proteins. 
On completion of filtration, the fusion proteins were eluted in protein elution buffer 
(Pierce Proteomics) in preparation for inoculation of the Balb/c mice. 
 
Balb/c Mice 
The 11 Balb/c mice used for antibody production (3 mice per antigen (9 in total) + 
2 control mice) were obtained from the University of Cape Town, Special 
Pathogen-free Animal Unit. Mice were housed in separate cages with freely 
available water and animal feed, supplied by the Medical Research Council South 
Africa. Cages were cleaned and maintained on a weekly basis. 
 
Antigen Preparation 
The eluted GST-fusion ORF3ΔN, MΔN and E viral proteins were quantified using 
a Bradford assay (BioRad). 250µl of 1X BioRad Bradford dye reagent (room 
temperature) was added to 5µl of the eluted proteins and 5µl of BioRad Bradford 
bovine serum albumin standards (at concentrations of 2.5mg, 2.0mg, 1.5mg, 
1.0mg, 0.75mg, 0.5mg, 0.25mg and 0.0mg/ml) in a 96 well microtiter plate. The 
absorbance (at 620nm) obtained for the Bradford standards were used to 
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construct a concentration trend straight line graph. The absorbencies of the eluted 
samples were substituted into the equation of the above mentioned straight line 
graph to obtain the concentration of the samples. 
Concentration of Antigens 
Protein samples were then concentrated using 5kDa molecular-weight-cut-off 
(MwCO), polysulfone membrane filters (Separations Biotech) and quantified again 
with a Bradford assay. 10ml of the GST protein elutes were centrifuge-filtered 
through the polysulfone filters at 10000rpm for 10min. 100μg aliquots of the 
isolated viral ORF3ΔN-, MΔN- and E-GST fusion proteins were supplemented 
with DPBS (Dulbecco’s modified Phosphate Buffered Saline) up to 150μl, before 
emulsification with an equal volume of Freund’s complete adjuvant (500µg/ml 
Mycobacterium butyricum suspended in 15% (v/v) Mannide Monooleate and 85% 
(v/v) Paraffin oil) (Life Technologies).  
 
Inoculation of Balb/C Mice 
Approximately 33μg (100µl) of each antigen solution was injected into each 
mouse intra-peritoneally, which constituted the primary inoculation. Each of the 
GST-fusion antigens were injected into 3 mice resulting in 9 mice being used for 
antibody production and 2 mice being reserved as a negative control (i.e. these 
mice were not inoculated). Mice were inoculated and left for 3 weeks before being 
boosted with 33ug of each antigen emulsified in Freund’s incomplete adjuvant 
(15% (v/v) Mannide Monooleate and 85% (v/v) Paraffin oil) (Life Technologies), 
every 2 weeks.  
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One week after the 4th, 5th and 6th booster injections, 15μl of blood was harvested 
from each mouse. Blood was obtained by clipping off ~2mm of tissue from the tip 
of the mouse’s tail and extracting blood from the transverse tail vein. The 
harvested blood was resuspended in 1.85ml sterile PBS. All procedures for the 
use of these laboratory animals were approved by the University of the Western 
Cape Animal Research Ethics Committee and carried out in accordance with the 
regulations and guidelines as stipulated by this committee. 
 
Validation of Antibody Production 
The resuspended blood was centrifuged at 3000rpm for 10min to separate the red 
blood cells from the antibody-containing mouse serum. ~1400μl of sera was 
isolated from each of the 11 mouse blood samples.  
 
Approximately 10μg of the GST-fusion viral proteins were separate by SDS-PAGE 
gel electrophoresis at 20mA/gel for 74min. The GST-fusion proteins was 
transferred by Western Blot onto PVDF (Polyvinylidene Fluoride) membrane 
(BioTrace) in a submersion, transfer system (Hoofer: Mighty Small Transfer) at 
100V, for 90min, with the use of a cooling system. The resultant membrane was 
soaked in Ponceau S (0.1% (w/v) Ponceau S (BioLab), 5% (v/v) acetic 
supplemented to 1L with distilled water) to verify protein transfer and for 
consistent protein-concentration loading verification, before being blocked in 
blocking solution (3% (w/v) fat free powder milk (BioRad) in phosphate buffered 
saline (PBS) containing 0.05% (v/v) Tween-20).  Next, the blot was cut into 3 
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strips thus isolating each GST-fusion antigen and 1 negative control on a 
separate piece of PVDF (Polyvinylidene fluoride) membrane.  
 
The sera from the first bleed, containing the mouse polyclonal antibodies against 
the GST-fusion viral proteins, were diluted 1:500 in 5ml of blocking solution (3% 
(w/v) fat-free milk (BioRad) in 1xPBS containing 0.05% (v/v) Tween-20). The 
individual blots were exposed overnight to the various mouse polyclonal 
antibodies at 4°C, with continuous rolling. Following the overnight incubation, the 
three blots were rinsed 3 times in 1X PBS (containing 0.05% (v/v) Tween-20) of 
15min. The secondary antibody, goat anti-mouse polyclonal conjugated with 
Horse Radish Peroxidase (Santa Cruz Biotechnology), was diluted 1:5000 in the 
blocking solution and exposed to the blots for one hour at room temperature with 
continuous rolling. The blots were once again rinsed in the PBS solution before 
being exposed to the HRP chromogenic substrate (KPL), at room temperature for 
~10min. Blots were photographed using a Canon (G6 Powershot) camera on a 
white background. 
 
As a result of the Western Blot, it was evident that the mouse antibodies were 
able to detect the GST-fused viral proteins. Detection of untagged viral proteins 
was imperative for the validation of specific antibody-antigen recognition. In an 
attempt to elucidate specific antibody activity, an ELISA (enzyme-linked 
immunosorbent assay) was executed. 
 
Indirect Viral Protein Specific ELISA 
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A flat bottom 96 well plate (Nunc-Immuno plate, MaxiSorp) was coated with 
50μl/well (10μg) of GST-fused viral protein in PBS and incubated overnight, at 
4°C. After 3 washings in wash buffer (autoclaved phosphate buffered saline and 
0.05% (v/v) Tween-20), non-specific binding sites were blocked with 1% (v/v) BSA 
(Bovine serum albumin) made up in PBS for 1 hour at R/T. A 50μl solution 
containing the diluted primary antibody (1:500 anti-GST-viral protein) constituted 
in PBS and added to all wells. This preceded a 1-hour incubation period at R/T, 
with orbital shaking. Subsequently, the plate was washed 3 times and 50μl of goat 
anti-mouse-horseradish peroxidase conjugate (1:5000 in PBS) was added to each 
well. Following an incubation period of 1 hour (at R/T with orbital shaking), the 
plate was washed 3 times in sterile PBS with 0.05% (v/v) Tween-20. 50μl of 
substrate solution (Tetramethybenzidine solution) was added to all wells and 
incubated for 10-15min at R/T. The chromogenic reaction was then stopped with 
the addition of 50μl/well of stop solution (1M H2SO4) and the absorbance was 
read spectrophometrically at 450nm (Original Multiskan EX, Type 355, Thermo 
Electron Corporation, Shanghai, China). The results of this ELISA displayed 
universal non-specificity of the antibodies resulting in protocol optimization. 
 
Optimization of ELISA’s Protocol 
In an attempt to optimize antibody specificity, 0.05% (v/v) Tween-20 was added to 
the blocking solution and the assay diluents for the primary antibody. The addition 
of a random GST-tagged antigens (10µg/well) to the primary antibody solution, 
resulting in an indirect viral protein specific competition ELISA, as a final attempt 
to further decrease the high GST affinity and non-specific binding observed. 
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CHAPTER 3 
 
Results and Discussion 
In silico Analysis 
The in silico analysis of the human coronavirus NL-63 ORF3 and M genes were 
carried out using Invitrogen’s peptide selector tool (http://peptideselect. 
invitrogen.com/peptide/). Whereas the hydrophilic state of the proteins was 
analyzed using the Kyte-Doolittle (1982) and Hopp-Woods (1981) selection 
criteria, the protein antigenicity was analyzed according to the Welling and Parker 
methods. 
 
  
 
 
 
Figure 4: NL-63 ORF3 Hydrophilicity and Antigenicity plot  
The above figure depicts increased hydrophilicity and antigenicity in the 3’ half of the HCoV-NL-63, ORF3 gene. Peaks 
protruding above the X-axis indicate the regions with increased hydrophilicity or antigenicity. 
 
Based on the results shown in Figures 4 and 5, the 3’-halfs of the ORF3 (from 
330nt to 678nt) and M (from 298nt to 681nt) genes were selected as the most 
 
 
 
 
CHAPTER 3____________________________________________________________________ 
Page 43 of 109 
immunogenic regions of the protein sequences based on amino acid polarity and 
membrane-surface orientation.  
 
The Kyte-Doolittle method used to calculate the antigenicity of proteins considers 
the molecular structure of each amino acid and assigns each one a hydrophilicity 
value between negative 4.6 (Hydrophilic) and positive 4.6 (Hydrophobic). The 
program then averages the hydrophilicity scores of every 9 amino acids to provide 
the user with a hydrophilicity plot for every section of the protein (Kyte and 
Doolittle, 1982). The Hopp-Wood method utilizes a similar method of calculating 
protein solubility with the exception of the suggested average window size being 7 
amino acids (Hopp and Woods, 1981).  
 
The Welling model for calculating antigenicity is based on comparing the 
functionality of the input amino acid sequences to that of known amino acid 
peptide epitopes with known antigenicity (Welling et al., 1985). Epitope similarity 
between the query protein and the known proteins suggests antigenic similarity. 
Similar to Welling’s method, the Parker method of calculating antigenicity also 
compares peptides to known antigenic strings of amino acids. However, the 
Parker method differs in that it accommodates the effect of various protein side 
chains when calculating antigenicity (Parker et al., 1994). 
 
The graphs indicated 3 hydrophobic regions in the 5’ halves of the ORF3 and M 
genes. For the purpose of antibody generation, the expressed tagged proteins 
would have to be soluble and not membrane bound in order to be isolated for 
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inoculation. This discovery led to the truncation of the undesired region in the 5’ 
halves of the proteins.  
For the purpose of this study primers were designed to amplify the 3’-portions 
ORF3 and M genes. Primers were also designed to amplify the entire E gene. All 
primers were designed to incorporate restriction enzyme sites for unidirectional, 
in-frame cloning of the inserts into vectors for expression in a bacterial system.  
  
 
 
 
 
Figure 5: NL-63 M Hydrophilicity and Antigenicity plot  
The figure above indicates the increased antigenicity in the 3’ half of the HCoV-NL-63 M gene according to the Welling and 
Parker methods. The Kyte-Doolittle and Hopp-Woods tests also showed more stable hydrophilicity in that same region of 
the gene. 
 
Forward primers consisted of a nucleotide sequence to append the restriction 
enzyme cut site for Sgf I, 1 or 2 additional nucleotides to allow for in-frame ligation 
of the viral genes into the expression vector, and 24 to 27 nucleotides 
complementary to the start of the section of DNA (ORF3- 330 to 355nt; M- 298 to 
225nt and E- 1 to 25nt) to be amplified on the complementary DNA strand. The 
reverse primer consisted of a nucleotide sequence to append the Pme I restriction 
enzyme site as well as 24 to 27 nucleotides, complementary end of the gene to 
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be amplified (ORF3- 654 to 678nt; M- 654 to 681nt and E- 177 to 201nt). These 
primers were then synthesized by Inqaba Biotech (Table 1, Page 27). 
Reverse Transcription and Gene Specific PCR 
Template viral RNA was extracted from infected Vero E6 cells (African Green 
Monkey kidney epithelial cells) and given to us as a kind gift from Professor Lia 
van der Hoek in Amsterdam. The RNA was used for first strand cDNA synthesis 
by reverse transcription using random primers. To ensure solubility of bacterially 
expressed viral recombinant proteins, only the predicted hydrophilic portions of 
proteins were amplified by polymerase chain reaction.  
 
Prior experiments have indicated difficulty when expressing insoluble viral 
proteins (Kondo et al., 2008). Therefore, polymerase chain reaction amplification 
of the hydrophilic portions of M and ORF3 (ORF3∆N and M∆N) and the complete 
E gene was done. The amplification products observed at ~350bp (Figure 6, 
Lanes 4 and 7, respectively) corresponded to the predicted size as determined by 
the in silico analysis, i.e. ORF3 (~360nt) and M (~390nt). The amplified product 
for the E gene, with an estimated size of ~250nt (Figure 7, Lane 3), corresponded 
to the predicted size of the in silico analysis. The accurate size of the amplicons is 
not a definitive indication of amplification of the genes of interest however, and it 
was decided to confirm the identity of the products by sequence verification. 
Therefore, products were purified and cloned for sequencing. 
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Figure 6: Gene specific PCR of ORF3ΔN and MΔN 
Figure 6 depicting a 100bp DNA marker in lane 1, the ORF3ΔN negative control (water) seen in lane 2, the amplified 
ORF3ΔN gene (~360nt.) in lane 4, the amplified MΔN gene (~390nt.) in lane 7 and the MΔN negative control (water) seen 
in lane 9. Lane 10 contains a 1Kbp DNA marker. 
 
 
 
 
 
 
 
 
Figure 7: Gene specific PCR of E 
The figure above depicts a 100bp DNA marker in lane 1, the E negative control (water) in lane 2 and the amplified E gene 
(~250nt.) in lane 3.  
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Ligation into the pGEM Vector for Sequencing  
Amplicons were gel purified to remove the ethidium bromide molecules and any 
salts that could interfere with the ligation process. The adenosine appended 
‘sticky ended’ purified genes were now ready to be ligated into pGEM T-Easy 
vectors, which were subsequently screened by blue-white colony selection. The 
pGEM T-Easy was used for three reasons: 
o This vector contains up-stream and down-stream M13 sequencing primer 
binding site, making it relatively easy and cost effective to sequence 
inserted products; 
o The 5’ and 3’ ligation sites found in the vector contain ‘T’ overhangs for 
easy ligation of ‘blunt ended’ PCR products into the vector; 
o The vector allows for Blue/White colony selection via the presence of a ß-
galacticidase. 
Selected white colonies were screened by genetic sequencing as discussed 
elsewhere. 
 
Transformation into the JM109 Competent E. coil 
pGEM constructs were transformed into JM109 chemically competent E. coli. 
Once the JM109 cells were heat shocked into accepting the pGEM constructs, 
cells containing unligated plasmids digest the substrate (X-gal) to produce a blue 
dye via the action of the ß-galacticidase gene. The presence of this die would 
result in a blue colony growing on the LB agar plate. Ligated plasmids with their 
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disrupted ß-galacticidase genes produced no dye and would thus results in white 
colonies. 
The positive transformation control plate, displaying only white colonies (Figure 
8), indicated the activity of the LacZ operon inducer (IPTG), the ß-galacticidase 
enzyme substrate X-gal and the efficacy of the pGEM-3Z vector transformation 
procedure. Figure 9 depicts the negative control transformation plate that 
displayed no growth and thus validated the antibiotic included in the semisolid 
media. The blue colonies observed on the background control plate (Figure 10) 
indicated the efficiency of the ligation reaction. These colonies contain religated 
pGEM vector, insert deficient with reconstructed LacZ operons which produced 
blue colonies. 
 
The blue and white colonies displayed on the experimental plates (Figures 11, 12 
and 13) showed a number of successfully ligated and transformed pGEM-viral 
gene constructs. The correct functioning of the experimental controls validated the 
white colonies observed on the experimental plates. 
 
 
 
 
 
 
Figure 8: Transformation into JM109 – Positive control 
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The numerous white colonies observed on the positive control plate, containing 100µg/ml ampicillin, indicate a successful 
transformation of the pGEM-3Z plasmid without an insert, into the JM109 competent E.coli cells.  
 
 
 
 
 
Figure 9: No Transformation into JM109 – Negative control 
The absence of the untransformed E.coli growth on the negative control plate (LB agar and 100µg/ml ampicillin) indicates 
the efficacy of the antibiotic used in the transformation experiments. 
 
 
 
 
 
Figure 10: Transformation into JM109 – Background control 
The blue colonies seen on the background control plate (LB agar and 100µg/ml ampicillin) validate the ligation procedure. 
The colonies seen here contain competent E.coli transformed with self-ligated pGEM t-Easy vector with no insert. 
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Figure 11: Transformation into JM109 – ORF3ΔN 
Both blue and white colonies are observed on this transformation plate (LB agar with 100µg/ml ampicillin). The white 
colonies seen here contain properly ligated pGEM t-Easy vectors with the viral ORF3 gene inserted, successfully 
transformed into the JM109 bacteria. 
 
 
 
 
Figure 12: Transformation into JM109 – MΔN 
Both blue and white colonies are observed on this transformation plate (LB agar with 100µg/ml ampicillin). The white 
colonies seen here contain properly ligated pGEM t-Easy vectors with the viral M gene inserted, successfully transformed 
into the JM109 bacteria. 
 
 
 
 
 
Figure 13: Transformation into JM109 – E 
Mostly blue colonies are observed on this plate (LB agar with 100µg/ml ampicillin). The white colonies seen here contain 
properly ligated pGEM t-Easy vectors with the viral E gene inserted, successfully transformed into the JM109 bacteria.  
 
Recombinant Vector Confirmation and Gene Sequencing 
10μl of the purified viral gene-pGEM constructs were sent to Inqaba Biotech for 
gene sequencing using the M13 universal sequencing primers. Figures 40, 41 
and 42 indicate the sequenced ORF3ΔN, MΔN and E genes in the pGEM vector.  
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Positive gene identification was made by firstly aligning the forward and reverse 
sequences obtained from the Inqaba Biotech. Next, the consensus sequence was 
compared to the 3’ half of the full-length ORF3 and M genes and the full length E 
gene available online from NCBI (NL-63-ORF3: AY697419, NL-63-M: AY697422 
and NL-63-E: AY697421). The homologies observed between the original 
sequences on the database and the experimentally determined sequences, 
validated the specificity of the designed primers for gene amplification. 
 
Sgf I and Pme I Restriction Enzyme Digest of pGEM Constructs 
The restriction digestion of the ORF3ΔN, MΔN and E-pGEM constructs resulted in 
the generation of ‘sticky ends’ that was ligated into the compatible sites of the 
GST bacterial expression vector. Whereas Figure 15 depicts the digested and 
sequence-verified viral E gene (~230bp), Figure 14 indicates the successful 
digestion of the sequenced ORF3ΔN (~350bp) and MΔN (~380bp) genes. The 
overhangs produced by this digestion allowed for the in-frame ligation of the viral 
genes into the bacterial expression vector, resulting in the production of the 
correct viral protein.  
 
 
 
 
 
 
 
 
 
 
______________________________________________________RESULTS AND DISCUSSION 
Page 52 of 109 
1   2       
500bp 
400bp 
300bp 
200bp 
Figure 14: Sgf I and Pme I digestion of ORF3ΔN and MΔN-pGEM construct 
Figure 14 above depicts a 100bp DNA marker lane 1, the released MΔN gene (~381nt) in lane 3 and the released 
ORF3ΔN gene (~348nt.) seen in lane 5. 
 
 
 
 
 
Figure 15: Sgf I and Pme I digestion of E-pGEM construct 
The figure above displays a 100bp DNA marker in lane 1 and the digested and released E gene (~234nt) in lane 2. 
 
pFLEXI Ligation and Transformation  
Sequence-verified pGEM-constructs were digested with Sgf I and Pme I and 
cloned into compatible sites of pFLEXI vector pFN2A (GST). The use of 
infrequent cutting restriction enzymes Sgf I and Pme I ensured the unidirectional 
cloning of the inserts into the vector. The pFLEXI vector also contains a lethal 
barnase gene that is disrupted during the process of ligation of inserts into the 
vector. The disruption of the barnase gene results in only properly ligated and 
transformed cells being able to grow in culture, therefore serving as its own 
positive control. Additionally, the vector contains two incompatible 5’- and 3’-end 
overhanging to prevent re-ligation of the vector with itself. The combinations of 
these characteristics result in the transformation experiment only requiring a 
negative control to validate the antibiotic used (Figure 16) and duplicate 
experimental plates for repeatability (Figures 17, 18 and 19). Thus, the single 
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white colonies observed on the experimental plates were a result of successful 
ligation and subsequent transformed of competent cells. 
 
 
 
 
 
 
Figure 16: Transformation into KRX – Negative control 
Here untransformed KRX bacteria were spread on an LB agar plate containing 100µg/ml ampicillin. The absence of 
bacterial growth validates the efficacy of the antibiotic utilized. 
 
 
 
 
 
Figure 17: Transformation into KRX- ORF3ΔN-GST 
Sparse growth observed on this plate indicates sub-optimal transformation of the ORF3ΔN-Flexi construct into the KRX 
bacteria. The LB agar used in this transformation contained 100µg/ml ampicillin.  
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Figure 18: Transformation into KRX- MΔN-GST 
Sub-optimal growth was observed for the growth of the MΔN-Flexi-transformed KRX bacteria. 100µg/ml ampicillin was 
added to the LB agar in order to discourage growth of any possible contaminant bacteria. 
 
 
 
 
 
Figure 19: Transformation into KRX- E-GST 
The multitude of white colonies observed on the plate above indicates optimal ligation and transformation of the E-Flexi 
construct into the KRX bacteria. Once again 100µg/ml ampicillin was used to prevent bacterial contaminant growth. 
 
pFLEXI Recombinant Plasmid Verification 
White colonies were selected from plates and recombinant plasmids were 
confirmed by restriction digestion analysis with Sgf I and Pme I for the correct 
insert size. This step is essential to ensure that the genes are still present and 
intact in the KRX expression bacteria before viral protein expression is induced. 
The bands seen at ~350bp (ORF3ΔN), ~380bp (MΔN) in Figure 20, and the band 
seen at ~230bp (E) in Figure 21, positively indicate the presence of the selected 
genes. Thus it is assured that the expressed proteins will be GST fusion proteins. 
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Figure 20: Sgf I and Pme I digest of ORF3ΔN and MΔN from pFLEXI constructs 
Figure 20 above displays a 100bp DNA marker in lane 1, the released ORF3ΔN gene (~350nt) in lane 3 and the released 
MΔN gene (~380nt) in lane 4.  
 
 
 
 
 
Figure 21: Sgf I and Pme I digest of E pFLEXI constructs 
The above figure depicts a 100bp DNA marker in lane 1 and the released E gene (~230nt) seen in lane 2. 
 
Pilot Study: Expression of MΔN-GST Fusion Protein 
A pilot study was conducted for two reasons: Firstly, to verify the efficacy of the 
proposed expression protocol and secondly, to gauge the time taken to reach 
optimal expressed protein concentrations. MΔN-GST was cultured to an optical 
density of ~0.2 (600nm) and induced with L-Rhamnose. Theoretically, expression 
should occur within 2Hrs of induction as previously seen (Tan et al., 2004; Keng 
et al., 2005). As seen in the Coomassie stain (Figure 22), optimal levels of protein 
concentration are only seen as late as 12Hrs post induction.  
1    2   
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Figure 22: 12 hour Pilot study - Coomassie stained SDS PAGE of expressed MΔN-GST 
fusion protein 
The figure above displays the supernatant of bacterial expression of MΔN-GST. Rainbow SDS protein marker is seen in 
lanes 1 and 10. 2hr, 4hr, 6hr, 8hr, 10hr and 12hr (lanes 3 to 8) supernatant showing optimal expression of MΔN-GST 
(~40KD.) is seen in lane 8 (at 12Hrs). 
 
It was evident from the results of the pilot study that protein expression only 
reached optimal levels 12hrs after induction which was much later than the 
expected 2 to 4 hrs post induction. As a result of this late induction, the 
expression procedure was modified by supplementation of the expression broth 
with 0.05% (w/v) glucose and 0.1% (w/v) L-Rhamnose at the inoculation stage. 
 
Expression of Viral GST Fusion Protein by Autoinduction 
Previous studies have shown that antibodies targeting coronaviral proteins 
expressed in bacteria are able to neutralize the virus in culture (Zhang et al., 
2004; Zhou et al., 2004; Keng et al., 2005). N and S coronaviruses proteins 
produced in bacteria have been utilized to generate in vivo antibodies that are 
able to detect NL-63 from clinical samples (Dijkman et al., 2008; Shao et al., 
     1   2     3    4     5    6     7    8    9   10 
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2007; Hofmann et al., 2005). Cross-reactivity observed between antigenic 
epitopes of coronavirus species does however hinder accurate diagnosis of 
infection (Chan et al., 2005). Our aim was to produce protein-specific antibodies 
that could ultimately be used for detection of virus and viral products in laboratory 
and clinical samples. To produce these antibodies, the E gene and the antigenic 
regions of the ORF3 and M genes were expressed as GST-tagged fusion proteins 
in a bacterial system.  
 
In our system, recombinant protein production was induced by the addition of L-
Rhamnose to the culture media. Also, the supplementation of glucose to the 
media allowed the E. coli cultures sufficient time to reach the optimal required cell 
density (i.e.: the equilibrium phase of bacterial growth) for effective metabolism of 
the L-Rhamnose and subsequent optimal induction of protein expression. As the 
bacteria preferably metabolize the glucose, L-Rhamnose metabolism, which 
induces protein expression, is delayed until all glucose in the medium is depleted. 
This cocktail of supplements resulted in the induction of expression approximately 
6 to 10Hrs after the culture was inoculated (Figures 23, 24 and 25).  
 
Expressed recombinant fusion proteins were extracted from the KRX bacterial 
cells and separated on 15% (w/v) SDS-PAGE gel, which resolves the negatively 
charged proteins through the acrylamide matrix based on the basis of their 
molecular weight. The observed molecular weights of the recombinant viral 
proteins (excluding the ~27kDa of the GST tag) was similar to the predicted MW 
of ORF3ΔN (~14kDa), MΔN (~15kDa) and E-GST (6kDa). It is important to 
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remember that the observed molecular weight of the recombinant proteins (ORF3: 
~42kDa, M: ~42kDa and E: ~36kDa) consists of the viral protein and the N-
terminal GST-tag.  
 
Coomassie Stain and Western Blot Analysis 
To determine the optimal expression conditions (time and temperature), a time 
course expression study was conducted over a 12-hour period for the ORF3-GST 
and M-GST mutant proteins; 36-hour time course was done for E-GST. The 
Coomassie Blue stain is used to stain proteins in polyacrylamide gels without 
permanently staining the gel. This allows the separated proteins to be visualized 
in the gel provided they are at a high enough concentrations. Staining of the SDS-
PAGE gels revealed the recombinant proteins at their expected size (Figures 23, 
24 and 25). 
 
It was however, also observed that the induction of protein expression was 
significantly later than expected. Whereas previous studies commonly report the 
expression of GST-coronaviral recombinant proteins as early as 2Hrs after 
induction in a bacterial system (Tan et al., 2004; Keng et al., 2005), the delayed 
response we observed in this study could possibly be attributed to viral proteins 
toxicity. Even though the expression procedure was carried out according to the 
manufacturer’s instructions (Promega, USA), optimal protein concentrations were 
only observed after 10Hrs post induction with L-Rhamnose and Glucose 
supplementation. This late induction indicated a prolonged exponential bacterial 
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growth phase before the bacteria reach their equilibrium-phase and protein 
production could begin. 
 
The presence of an unstable promoter sequence in an expression vector has 
been seen to result in low levels of toxic protein expression during both the initial 
and lag phases as observed in this study (Giacalone et al., 2006). The 
background toxic expressions result in reduced bacterial growth and thus a 
delayed onset of bacterial equilibrium phase. As full scale induction only occurs at 
the final phase of bacterial growth, when the glucose in the media has been 
metabolized and the bacteria start to utilize the L-Rhamnose, latent protein 
expression is observed.  
 
Even so, researchers do advise the use of a T7 promoter to allow for tight 
regulation of toxic protein expression in bacteria (Tabor and Richardson. 1985). 
Coupled with the use of a rare inducer, such as L-Rhamnose, the tightly 
regulating T7 promoter should have resulted in more stringently controlled 
expression. 
 
A variety of procedures were explored to reduce the delay of protein expression 
induction. One of these methods included expression of proteins at 27°C, with 
continuous shaking (150rpm), to reduce basal toxic protein expression during the 
bacterial growth phase. Another method attempted to decrease the latency of 
protein expression was the addition of 1mM IPTG to the expression broth. The 
addition of IPTG more stringently control expression and reduces background 
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toxic protein expression levels. Both attempts to reduce the delayed expression 
were unsuccessful.  
 
The time course experiments however revealed the highest titer of ORF3 proteins 
12Hrs after induction and at 10Hrs for M protein. The highest titers of E-GST 
proteins were observed after 16Hrs. The expression times with the highest protein 
titers were used in the final large-scale expression to obtain the greatest antigen 
concentration for the mouse inoculations. 
 
 
 
 
 
 
Figure 23: Coomassie stain displaying optimal ORF3ΔN-GST fusion protein expression at 
12 hours  
The Coomassie stained gel above depicts the optimal concentration of bacterially expressed of ORF3ΔN-GST (~41kDa) at 
12 hours post induction (lane 8). A rainbow SDS protein marker is seen in lanes 1 and 10, and the 2, 4, 6, 8 and 10 hour 
supernatant see in lanes 3 to 9. 
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Figure 24: Coomassie stain showing an optimal concentration of expressed MΔN-GST 
fusion protein at 10 hours post induction. 
The Coomassie stained gel above displays the optimal concentration of bacterially expressed of MΔN-GST (~42kDa) at 10 
hours post induction (lane 7). A rainbow SDS protein marker is seen in lanes 1 and 10, and the 2, 4, 6, 8 and 12 hour 
supernatant see in lanes 3, 4, 5, 6 and 8 respectively 
. 
 
 
 
 
 
 
Figure 25: Coomassie stain depicting optimal expression of E-GST fusion protein 16 hours 
post induction. 
The Coomassie stained gel above depicts the optimal concentration of bacterially expressed of E-GST protein (~34kDa) at 
16 hours post induction (lane 6). A rainbow SDS protein marker is seen in lanes 1 and 10. Lanes 2, 3, 4, 5, 7, 8 and 9 
contain the supernatants of the 8, 10, 12, 14, 18, 24 and 36 hour samples, respectively. 
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Western blotting verified the presence of the fusion proteins with the use of GST 
specific antibodies (Figures 26, 27 and 28). The specific binding of the antibodies 
at the correct proteins validated the presence of the tagged proteins. 
 
 
 
 
Figure 26: Western Blot showing an optimal concentration of ORF3ΔN-GST expressed 
fusion protein, 12 hours post induction 
Rainbow SDS protein marker is seen in lane 1. Lanes 3 to 7 displays the 4, 6, 8, 10 and 12 hour supernatant, showing an 
optimal concentration of expressed ORF3ΔN-GST (~41kDa) at 12 hours (lane 7). 
 
 
 
 
 
 
Figure 27: Western Blot displaying an optimal concentration of MΔN-GST expressed fusion 
protein, 10 hours post induction 
Rainbow SDS protein marker is seen in lane 1. Lanes 3 to 7 displays the 4, 6, 8, 10 and 12 hour supernatant, showing an 
optimal concentration of expressed MΔN-GST (~42kDa) at 10 hours (lane 6). 
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Figure 28: Western Blot of E-GST expressed fusion proteins displaying an optimal protein 
concentration at 16 hours post induction. 
The rainbow SDS protein marker is seen in lanes 1 and 10. Lanes 2 to 9 consists of the 8, 10, 12, 14, 16, 18, 24 and 36 
hour supernatant samples, respectively. Lane 6 shows the optimal concentration of the expressed E-GST fusion protein 
(~34kDa) at 16 hours post induction. 
 
Antigen Preparation 
Once the proteins were isolated from the expression bacteria and filtered through 
the purification columns, they were quantified using a Bradford assay. Figure 29 
indicates the standard curve as obtained from the Bradford Assay kit standards.  
The specific protein concentrations of the GST-fusion proteins ORF3ΔN, MΔN 
and E (Figure 30) were obtained using the Bradford standard curve equation from 
Figure 29.  
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Figure 29: Bradford Assay Standard Curve (620nm) 
This figure above indicates the optical densities (Y-axis) of the Bradford assay standards in relation to their concentration 
which ranges from 0mg/ml to 2mg/ml, as seen on the X-axis.  
 
 
 
 
 
 
 
 
 
 
Figure 30: Concentration of GST-Fusion viral protein post purification  
Figure 30 above depicts the concentrations of the GST-fusion viral proteins as calculated by substituting the optical 
densities of the purified protein samples into the equation obtained from the Bradford standard curve in Figure 29. 
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Results indicated that the antigens MΔN and E were at concentrations greater 
than 1mg/ml, which was optimal for the inoculation of the mice. The ORF3ΔN 
antigen was however, seen to be at a concentration of 0.75mg/ml and needed to 
be concentrated for optimal affectivity. 
 
Concentration of Antigens 
GST-fusion proteins were concentrated by centrifuge-filtering through 5kD 
molecular weight cut off filters. The resultant samples were once again assayed to 
determine their protein concentrations as indicated in Figures 31 and 32 below. 
 
 
 
 
 
 
Figure 31: Bradford Assay Standard Curve (620nm) 
Figure 31 indicates the optical densities (Y-axis) of the Bradford assay standards in relation to their concentration which 
ranges from 0mg/ml to 2mg/ml, as seen on the X-axis.  
  
The optical densities of the concentrated GST-fusion proteins were substituted 
into the formula of the standard curve generated by the graph in Figure 31. The 
resultant concentration is seen in Figure 32 below. It was evident from the 
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increased optical densities that the proteins had a significantly higher 
concentration. 
 
Figure 32: Concentration of GST-Fusion Viral Protein Post Purification 
Figure 32 above depicts the concentrations of the GST-fusion viral proteins as calculated by substituting the optical 
densities of the concentrated purified protein samples into the equation obtained from the Bradford standard curve in 
Figure 31. 
 
Validation of Antibody Production 
The production of polyclonal antibodies begins with the immunization of the mice 
with the fusion viral proteins (produced in E. coli) suspended in Freund’s complete 
adjuvant. The preferred route of inoculation in this case was subcutaneously 
(intrapertonially) as opposed to intramuscularly as described by Hendriksen and 
Hau (2003). The function of the immune system is to eliminate non-self of foreign 
objects from the body (Kidd, 2003) and the exposure of host’s immune system to 
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the viral fusion antigens sets off an immune response (von Behring and Kitasato, 
1890). 
 
The production of specific antibodies can be divided into 3 phases namely: the 
inductive phase, the effector phase, and the establishment of immunological 
memory (McCullough et al., 1997). The innate immune system consists of Natural 
killer cells, mast cells, eosinophils, basophils and the phagocytic or antigen 
presenting cells (APC) which include macrophages, neutrophils and dendritic 
cells. These immune cells are the first to encounter the foreign antigen in the 
mouse’s body and initiate the immune response (Randall et al., 2008).  
 
The antigen is internalized and processed by the APC’s and displayed on the 
surface of the APC along with major histocompatibility complex molecules (MHC) 
which attract the antigen receptors on the T-cells (thymus-derived lymphocytes). 
The contact between the antigen, the MHC molecules and the T-cell activates the 
T-cells. This primary exposure, antigen processing and T-cell activation constitute 
the inductive phase. 
 
When dealing with a protein antigen, the T-cell will employ the help of a T-helper 
(Th) cell. This action marks the beginning of the effector phase. The activated Th 
cells become sensitized to growth factors such as the cytokine interleukins 1 and 
2 (IL1 and IL2) that are released by the distressed cells at the site of the 
immunization. These cytokines will eventually cause the B-lymphocytes to 
proliferate and differentiate into antibody producing plasma cells. Every single 
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plasma cell is genetically programmed to produce a specific antibody that will only 
recognize a single antigen epitope. These antibodies, also called 
immunoglobulins can be divided into 5 basic classes: IgA, IgD, IgE, IgG and IgM 
each with their own specific ranges of activity.  
 
An antigen epitope usually comprises of between 5 and 10 amino acids. Hence, 
the viral-fusion tag antigens would consist of quite a number of antigen epitopes, 
and would require antibodies from more than one stimulated B-cell. Thus, the 
immunological response to such larges antigens requires a combination of 
hundreds of monoclonal antibodies against the various epitopes. 
 
The induction of memory phase relies on the prior exposure to antigens of 
pathogens (Ladics, 2007; Vos and Loveren, 1998). Immune system memory 
relies on the differentiation of the B-cells and makes the response to secondary 
exposures, more rapid. In the case of the bi-weekly booster immunizations, the 
IgG concentration would greatly outweigh that of IgM and the immunological 
response is more effective (McCullough et al. 1997). 
 
After the second inoculation, the mice were bled to determine the presence of 
antibodies. Harvesting of antibodies is carried out by the collection of blood serum 
via the lateral tail bleed method as described by Loeb and Quimby in 1999. The 
polyclonal immunoglobulins found in the blood plasma are separated from the 
blood cells and diluted in phosphate buffered saline and used for Western Blotting 
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and ELISAs. The Western Blot seen in Figure 33 below verifies the presence of 
antibodies specific to GST-fusion viral proteins at a concentration of 1:500.  
 
 
 
 
 
 
 
Figure 33: Western Blot using 1:500 Mouse anti-GST-Fusion 1˚ Antibodies 
This figure depicts a positive Western Blot for the presence of the anti GST-fusion mouse antibodies produced as a result 
of the inoculations with the fusion antigens. Rainbow SDS page marker Lane 1; MΔN-GST (~42KDa.) Lane 3; ORF3ΔN-
GST (~41KDa.) Lane 4; and E-GST (~34kDa) in Lane 5. (Negative control lanes not shown.) 
 
The GST-tagged proteins isolated were seen to be of the expected molecular 
weight (GST~25kDa + ORF3~7kDa / M~11kDa or E ~9kDa) when in comparison 
to the protein marker (Prosieve). The activity of the produced antibodies was thus 
validated. Antibody specificity was yet to be determined. 
 
Viral Protein specific ELISA  
An ELISA was conducted to determine the specificity of the produced antibodies. 
Theoretically, each antibody has been produced with an affinity to both GST and 
the viral antigens. Hence this indirect ELISA was used to investigate GST affinity 
and viral protein specificity. 
55kDa 
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The results depicted in Figure 34 below suggest poor specificity of the antibodies 
to their corresponding viral antigens. It can thus be deduced that the high 
immunogenicity of the GST tag fused to the viral protein far outweighed that of the 
viral protein itself.  
 
 
 
 
 
 
Figure 34: Absorbance observed for the indirect ELISA 
The above graph indicates the average absorbance observed for the wells coated with the antigens GST-ORF3 (shaded 
blue), GST-M (shaded maroon) and GST-E (shaded yellow). No definitive antibody specificity is observed. 
 
There are various scientifically proven solutions to counteract the great 
immunogenicity of the GST fusion tag. Cleavage of the fusion tag from the viral 
protein using a TEV (Tobacco Etch Virus (Promega)) protease would eliminate 
the strong GST affinity seen in the Western Blots and ELISAs and thus validate 
the specificity of the produced antibodies. Despite numerous attempts, we were 
unable to successfully perform this experiment. The indirect ELISA procedure was 
thus modified to render antibody binding more specific. 
 
 
anti-ORF3 anti-M anti-E 
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Optimized, Indirect, Viral Protein Specific ELISA 
The previous ELISA was repeated with the addition of 1% BSA to all solutions in 
an attempt to reduce non-specific, GST binding. The graph below (Figure 35) 
demonstrates the results of this modification to standard procedure. 
 
Figure 35: Absorbance observed for the optimized, indirect ELISA  
Figure 35 above indicates the average absorbance observed for the wells coated with the antigens GST-ORF3 (shaded 
blue), GST-M (shaded maroon) and GST-E (shaded yellow). No significant antibody specificity was observed. 
 
From the data obtained it is evident that the addition of BSA to the ELISA 
solutions had minimal effect on the non-specific binding to GST. Results still 
indicated minimal binding affinity to the targeted viral proteins. The ELISA 
procedure was once again modified to achieve the desired result. 
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Optimized Indirect Viral Protein Specific Competition ELISA 
Random, GST-tagged proteins were incubated with the primary antibodies to 
neutralize GST affinity. The remaining active antigen binding sites would thus be 
specific for the targeted viral proteins. The results of this ELISA, seen below 
(Figure 36), indicate no significant levels of antibody-viral protein specificity. 
 
 
 
 
 
 
 
 
 
Figure 36: Absorbance observed for the optimized, indirect, competition ELISA 
The above graph indicates the average absorbance observed for the wells coated with the antigens GST-ORF3 (shaded 
blue), GST-M (shaded maroon) and GST-E (shaded yellow) and competed with the antigens listed n the X-axis. 
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CHAPTER 4 
 
Conclusion 
Acute respiratory illnesses (ARIs) are a major health concern worldwide. 
Worldwide, ARIs affect all age groups and remain the leading cause of infant and 
young children mortality, accounting for approximately 2 million deaths annually 
(Kieny and Girard, 2005; Mizgerd, 2006). These deaths exert an economic burden 
on healthcare systems, especially in third world countries. Even though 
rhinoviruses, influenza viruses, parainfluenza viruses, respiratory syncytial 
viruses, adenoviruses and coronaviruses have been shown to be most frequently 
associated with respiratory infections, a significant proportion of these respiratory 
tract infections have no known cause. Recently, two new coronaviruses have 
been implicated in a number of these infections (van der Hoek, et al., 2004; Woo 
et al., 2005).   
  
It has previously been reported that human coronaviruses account for a significant 
number of hospitalizations for children under 18 years of age, accounting for 4.4% 
of all admissions for acute respiratory infections. Interestingly, in a recent study of 
human coronavirus infections, the newly discovered human coronavirus NL-63 
was the most common coronavirus identified (Chiu et al., 2005). Initial clinical 
data indicate that HCoV-NL-63 causes acute respiratory disease in young infants 
and in immunocompromised adults and was detected in 1.3%-8.8% of respiratory 
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samples tested (Arden et al., 2005; Bastien et al., 2005; Chiu et al., 2005; Ebihara 
et al., 2005; Suzuki et al., 2005; Vabret et al., 2005; Chung et al., 2007; Han et al., 
2007) and can also present as asthma exacerbation, febrile seizures and high 
fever (Chiu et al., 2005). 
NL-63 contains a single strand of positive sense, poly adenylated RNA strand, 
which resembles the host cell’s mRNA. After the viral entry and uncoating, 
sections 1a and 1b on the 5’ end of the RNA genome are directly translated into 
the viral enzymes required for viral progeny by the host cells cytoplasmic 
ribosomes. The self-encoded viral replicase enzymes (RNA dependant RNA 
Polymerase and viral protease) produced are deficient in mammalian cells and 
require a –1 ribosomal frame shift to express gene 1b, in frame (Herold et al. 
1993; Giedroc et al. 2000). The action of these enzymes brings about the 
formation of new virions through the cytoplasmic production of viral proteins. The 
virus however, does not encode a proofreading viral enzyme and transcription 
and translational errors and point mutations are common with such huge, 
unstable RNA genomes.  
 
Enzyme linked immunosorbent assays (ELISA) have previously been used to 
detect NL-63 specific antibodies (Dijkman et al., 2008; Shao et al., 2007). These 
N-specific ELISA assays were used to screen serum samples from children under 
the age of 20 (Shoa et al., 2007). These ELISAs were able to detect maternally 
acquired N-directed antibodies (Dijkman et al., 2008; Shao et al., 2007), which 
normally decrease within the first 4-5 moths of life (Shao et al., 2007). Another 
study conducted by Hofmann et al. (2005), positively identified NL-63-S protein in 
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almost all samples isolated from children under the age of eight (Hofmann et al., 
2005). Combined, these findings suggest that NL-63 infections are commonly 
acquired during the early stages of life. 
 
Serological cross-reactivity has been observed between SARS-CoV and other 
HCoVs including NL-63 (Chan et al., 2005). This phenomenon has previously 
been observed specifically when using immunoflourescence and complement 
fixation assays (McIntosh et al., 1974; Monto and Rhodes, 1977). Even ELISA’s 
specific to recombinant N proteins of SARS-CoV detected false positives (Woo et 
al., 2004). Chan et al. (2005) suggest that this antigenic cross-reactivity is as a 
result of the presence of cross-reactive antigenic epitopes of the coronaviruses. 
Antigenic cross-reactivity is a key factor to consider when attempting developing 
serological diagnostic assays for coronaviruses. 
 
Here, we generated cDNA from HCoV-NL-63 RNA and used to amplify the E 
gene as well as the hydrophilic regions of ORF3 and M for expression in a 
bacterial system. These hydrophilic regions were chosen to increase the solubility 
of the fusion proteins expressed in the bacterial system for improved ease of 
purification. SDS-PAGE and Western-Blotting techniques, using anti-GST 
antibodies, were used to confirm the presence of the over expressed GST-fusion 
proteins, GST-M, GST-ORF3 and GST-E. The fusion proteins were soluble and 
high levels were detected in the lysate portion of our bacterial cultures.  
These expressed fusion proteins served as the antigens, which were presented to 
the mouse immune system, in an attempt to the generate antibodies for use in 
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basic research, as well as for the screening of clinical samples for the presence of 
HCoV-NL-63.   
 
The procedures for in vivo antibody production are both invasive and time 
consuming and require the use of immunopotentiating products (adjuvants) to 
enhance the immune response (Hendriksen and Hau 2003). These undesirable 
effects are however necessary for the production of polyclonal antibodies (Amyx, 
1987) and result in animal experiments being tightly regulated by the universities 
animal handling and ethics committees. 
 
In this study, gene amplification and primer specificity has been validated by the 
correct band sizes seen for both the ORF3 and M gene mutants and the native E 
gene in ethidium bromide gel electrophoresis. The genes were later verified by 
genomic sequencing and in silico analysis proved them to be homologous to the 
online genbank sequences. These validated genes were subsequently ligated into 
a bacterial expression vector and later verified by restriction enzyme digestion. 
Western Blot analysis of bacterially expressed GST-tagged viral-fusion proteins 
revealed high concentrations of tagged proteins at the expected molecular 
weights in the bacterial lysates. 
 
Expressed viral-fusion proteins were purified by gravity filtration through GST-
affinity agarose columns before being quantified by Bradford assay and 
concentrated for in vivo antibody production in mice. Two weeks after inoculation, 
mice were administered booster shots to increase blood-antibody titers. 
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Antibodies were harvested from the lateral tail vein and suspended in sterile PBS. 
In vivo antibody sensitivity was validated by Western Blotting before specificity 
determination was attempted using a modified indirect competition ELISA. 
To date, the antibodies generated in this project are seen to be active and 
capable of detecting GST tagged viral proteins. Specificity of the antibodies is yet 
to be determined and will require further experimentation and resources. Once 
specificity has been validated, the ability of these antibodies to differentiate 
between viral species present in clinical samples may be hindered by the huge 
similarities observed between HCoV NL-63 and HCoV 229E. 
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Figure 37: Sequencing vector pGEM T-easy 
 
 
 
 
 
 
 
 
 
Figure 38: Positive control vector pGEM-3Z 
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Figure 39: Bacterial expression vector pFLEXI-pFN2A (GST) 
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Figure 40: Sequence verification of ORF3ΔN gene in pGEM 
Figure 40 above depicts the homology between the Human Coronavirus NL-63 (Amsterdam 1 strain) ORF3 sequence and 
the consensus of the forward and reverse sequences obtained from the pGEM-ORF3∆N amplicons which were sent to 
Inqaba biotech for ABi sequencing. 
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Figure 41: Sequence verification of MΔN gene in pGEM 
Figure 41 above depicts the homology between the Human Coronavirus NL-63 (Amsterdam 1 strain) M sequence and the 
consensus of the forward and reverse sequences obtained from the pGEM-M3∆N amplicons which were sent to Inqaba 
biotech for ABi sequencing. 
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Figure 42: Sequence verification of E gene in pGEM 
Figure 42 above depicts the homology between the Human Coronavirus NL-63 (Amsterdam 1 strain) E sequence and the 
consensus of the forward and reverse sequences obtained from the pGEM-E amplicons which were sent to Inqaba biotech 
for ABi sequencing. 
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